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Advances in molecular pathology have changed the landscape of oncology. The ability
to interrogate tissue samples for oncogene amplification, driver mutations, and other
molecular alterations provides clinicians with an enormous level of detail about their
patient’s cancer. In some cases, this information informs treatment decisions, especially
those related to targeted anti-cancer therapies. However, in terms of immune-based
therapies, it is less clear how to use such information. Likewise, despite studies
demonstrating the pivotal role of neoantigens in predicting responsiveness to immune
checkpoint blockade, it is not known if the expression of neoantigens impacts the
response to targeted therapies despite a growing recognition of their diverse effects
on immunity. To realize the promise of ‘personalized medicine’, it will be important to
develop a more integrated understanding of the relationships between oncogenic events
and processes governing anti-tumor immunity. One area of investigation to explore
such relationships centers on defining how ErbB/HER activation and signal transduction
influences antigen processing and presentation.
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INTRODUCTION AND OVERVIEW
Stated simply, oncogenic events are not immunologically null (Seliger, 2014). Defining the
immunologic impact of oncogenic events will be a critical area of research as advances in
molecular diagnostics parallel the expansion and availability of cancer immunotherapy (Whiteside
et al., 2016). Alterations in DNA sequence, copy number variation (CNV), transcriptional
profile, and epigenetics can all influence the expression of genes of the immune system,
immunologic processes, and ultimately anti-tumor immunity. The importance of antigen
processing and presentation in this regard is underscored by recent studies that have defined
the impact of mutation-derived neoantigens on the response to immune checkpoint blockade
Frontiers in Pharmacology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 2
Kersh et al. ErbB/HER Signaling and MHC Expression
(Sorensen et al., 2009; van Rooij et al., 2013; Schumacher et al.,
2014; Snyder et al., 2014; Kelderman et al., 2015; Le et al., 2015;
Van Allen et al., 2015). These recent findings, further highlight
the importance of defining interactions between oncogenes,
oncogenic signal transduction, and the antigen processing
machinery (APM) (Seliger, 2014). Moreover, because the APM
plays a critical role in cancer immunoediting, understanding
how anti-cancer therapies (of all types) influence the APM will
be equally important (Galluzzi et al., 2012; Wargo et al., 2014;
Okwan-Duodu et al., 2015; Ward et al., 2016). The goal of this
article is to provide a framework for understanding interactions
between oncogenic ErbB/HER signal transduction and the APM,
using the expression of major histocompatibility complex (MHC)
molecules as a model.
Oncogenes and the APM – General
Considerations
Recent studies confirming the relevance of neoantigens, also
referred to as tumor specific antigens (TSA), provides enormous
rationale to understand how oncogenic events impact the
ability of tumor cells to process and present antigenic peptides.
Moreover, being able to pharmacologically manipulate the
expression of proteins that make up the APM takes on
additional relevance since defects within the APM are common
in human cancer and such alterations will likely influence the
peptide-MHC (pMHC) repertoires presented by tumors cells
(Seliger et al., 2000; Garrido et al., 2016). The dual ability of
ErbB/HER signaling to modulate large transcriptional programs
and influence MHC expression suggests that alterations in
the ErbB/HER family of ligands and/or receptors will change
the pMHC repertoire present at the surface of tumor cells.
Alterations of ErbB/HER receptors and ligands occurring in
human cancer are shown in Tables 1 and 2. This concept was
supported by the fact that ErbB/HER ligands and receptors
can greatly influence the cellular transcriptome, which in turn
influences the pMHC repertoire (Choi et al., 2007; Fortier et al.,
2008; Nagashima et al., 2008). In addition, the complex nature of
ErbB/HER signaling that results from having numerous ligands,
receptors, and mechanistically distinct activating events, supports
the idea that there will be differential effects on MHC expression.
While it will likely be cell-context dependent, defining ErbB/HER
oncogenic signaling in this manner provides an experimental
approach that can further our understanding of interactions
between oncogenes and immunity. Moreover, this approach
lends itself to validation using cell-based systems, genetically
engineered mouse models, and human pathology samples. Some
of these concepts are shown in Figure 1.
A Brief Overview of MHC Molecules
Major histocompatibility complex molecules are cell surface
glycoproteins that function to present self- and antigen-derived
TABLE 1 | Alterations of ErbB/HER receptors in human cancer.
Receptor Mutation/Modification Cancer Reference
EGFR/ErbB1/HER1 Overexpression Colorectal carcinoma Moroni et al., 2005
Substitutions G719S, L858R NSCLC Paez et al., 2004
Activating in-frame kinase domain deletions NSCLC Lynch et al., 2004
Overexpression, activating deletions
(truncation), EGFRvIII (801 bp in-frame
deletion of extracellular domain, activating)
Glioblastoma Watanabe et al., 1996; Frederick et al.,
2000; Paff et al., 2014
Overexpression and cytoplasmic
expression
Cutaneous SCC Canueto et al., 2016
Overexpression Head and neck SCC Grandis and Tweardy, 1993
Overexpression Esophageal adenocarcinoma Al-Kasspooles et al., 1993
ErbB2/HER2/NEU Overexpression Breast carcinoma Carey et al., 2006; Howlader et al., 2014
Overexpression Gastric carcinoma Falck and Gullick, 1989; Tanner et al., 2005;
Yano et al., 2006; Hofmann et al., 2008
Insertion, overexpression NSCLC Weiner et al., 1990; Oxnard et al., 2013
Overexpression Bladder carcinoma Neal et al., 1985; Sato et al., 1992; Sauter
et al., 1993
Overexpression Pancreatic carcinoma Yamanaka et al., 1993b; Lei et al., 1995
Overexpression Ovarian carcinoma Meden and Kuhn, 1997
Overexpression Endometrial carcinoma Saffari et al., 1995; Rolitsky et al., 1999
Overexpression Head and neck SCC Beckhardt et al., 1995
Overexpression Esophageal adenocarcinoma Al-Kasspooles et al., 1993
ErbB3/HER3 Substitution V855A (homologous to
EGFR-L858R)
NSCLC Umelo et al., 2016
Overexpression Oral SCC Shintani et al., 1995
ErbB4/HER4 Missense mutations resulting in increased
kinase activity
Melanoma Prickett et al., 2009
Missense/insertions/deletions in kinase
domain
Gastric, breast, lung and colorectal
carcinomas
Soung et al., 2006
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TABLE 2 | Alterations of ErbB/HER ligands in human cancer.
Ligand Mutation/Modification Cancer Reference
Epidermal growth factor (EGF) Overexpression Pancreatic Yamanaka et al., 1993a
Point mutation Gastric Wu et al., 2015
Transforming growth factor-α (TGF-α) Overexpression Prostate Scher et al., 1995
Overexpression Pancreatic Yamanaka et al., 1993a
Overexpression Lung, ovarian, colon Salomon et al., 1995; Rusch et al., 1997
Neuregulin/ Heregulin 1 (Nrg1/Hrg1) Overexpression Breast carcinoma Raj et al., 2001; Slattery et al., 2013
Chromosomal translocation Breast carcinoma Huang et al., 2004
Amphiregulin(AREG) Overexpression Ovarian Niikura et al., 1997
FIGURE 1 | Possible mechanisms through which ErbB/HER oncogenic activating events influence the peptide-MHC (pMHC) repertoire. ErbB/HER
oncogenic events may influence the peptide-MHC repertoire via several possible mechanisms. ErbB/HER oncogenic activation alters the transcriptome of tumor
cells which may include the expression of tumor associated antigens and tumor specific antigens (TSA) such as neoantigens. By altering the transcriptome of tumor
cells, ErbB/HER oncogenic events influence the pool of available proteins available for antigen processing and presentation. In addition, ErbB/HER oncogenic
signaling may influence the expression of components of the antigen processing machinery (APM) including MHCI and MHCII molecules directly or indirectly by
altering the cellular response to cytokines. This will alter the nature and density of the pMHC repertoire. Qualitatively and quantitatively, the nature of the pMHC
repertoire may influence T cell-mediated anti-tumor immune responses.
peptides to cells of the immune system. In humans, MHC
molecules are encoded by human leukocyte antigen (HLA)
genes and these terms are often used interchangeably. MHC
class I (MHCI) molecules consist of two polypeptide chains,
the alpha chain (HLA-A, B, C) and ß2-microglobulin which
are non-covalently associated on the cell surface. The alpha-
1 and alpha-2 domains of the MHC class I molecule form
the peptide binding cleft which binds and presents cytosol-
derived peptides that are 8−11 amino acids in length to
CD8 T lymphocytes (Comber and Philip, 2014). As MHCI
molecules function in concert with CD8 T cells for immune
surveillance against infections and malignancies, these molecules
are expressed on the surface of virtually all nucleated cells and
MHCI expression can be further increased (induced) by type
I and type II interferons (IFNs) as well as other cytokines.
Underscoring their important role in controlling malignancies
and infections is the fact that tumor cells and microbes alike such
as the human immunodeficiency virus (HIV) and Mycobacterium
tuberculosis (Mtb) harbor mechanisms that down-regulate MHCI
expression to facilitate immune escape (Ferris et al., 2006;
Pennini et al., 2006; Choma et al., 2015; Concha-Benavente et al.,
2016).
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MHC class II (MHCII) molecules function to present antigen
to CD4 T lymphocytes generating helper T cell responses that are
critical for effective adaptive immune responses against infection
and cancer (DeSandro et al., 1999; Accolla et al., 2014). Each
MHCII molecule (HLA-DR, DP, DQ) is composed of an alpha
and beta polypeptide chain that non-covalently associate at the
cell surface with one subunit from each chain forming the peptide
binding cleft. MHCII molecules bind peptides of 13−17 amino
acids in length that are generated by proteolysis in lysosomes
and endosomes and are constitutively expressed on the surface
of antigen presenting cells (APCs) such as B cells, macrophages,
and dendritic cells (DCs; Roche and Furuta, 2015).
In order to understand how oncogenic signal transduction
might influence the expression of MHC molecules, it is important
to review some aspects of MHC expression regulation. In
general, though not exclusively, MHC molecules are regulated
transcriptionally and epigenetically (van den Elsen et al.,
2004; Choi et al., 2011; Kobayashi and van den Elsen, 2012).
This regulation is orchestrated at several levels involving
complex interactions between regulatory DNA sequences, within
the MHC locus (such as promoters and enhancers), DNA-
binding transcription factors (TFs) that bind these sequences,
transcriptional co-activators (NLRC5/CITA for MHCI and
CIITA for MHCII) and the formation of complex looping
structures that involve interactions with epigenetic enzymes and
chromatin (Gobin et al., 2001; Meissner et al., 2012). There are
many excellent detailed reviews available on the regulation of
MHCI and MHCII molecules (van den Elsen et al., 1998; van den
Elsen, 2011; Devaiah and Singer, 2013; Neerincx et al., 2013).
When considering interactions between oncogenic signaling
and MHCI expression, two types of expression need to be
considered. Constitutive expression refers to the level of MHCI
molecules expressed under physiologic conditions and varies
between different tissues due in part to differences in epigenetic
marks (Kotekar et al., 2008). In addition to constitutive
expression, increases that occur in response to cytokines are
referred to as inducible expression. Defects in both types of
MHCI expression occur in human cancer (Garrido et al., 2010).
Mechanistically, constitutive MHCI expression is regulated by
distinct regions within MHCI promoters that are binding sites for
TFs such as NFkB, IRF-1, and CREB. The inducible expression
of MHCI molecules occurs in response to cytokines such as
type I and type II interferons (IFNs) and tumor necrosis factor-
alpha (TNF-α) and is mediated through changes in TFs, co-
activators, and other proteins that occur in response to the
inducing cytokine (van den Elsen, 2011). Thus, when considering
interactions between ErbB/HER signaling and MHC expression,
the status of both constitutive and inducible MHCI expression
warrant attention.
In contrast to MHCI, MHCII is expressed constitutively only
on specialized cells of the immune system such as DCs and B
cells. The expression of MHCII is regulated largely via the activity
of the MHCII co-activator (CIITA) which itself is regulated by
distinct promoters that are active in DCs and B cells (named
pI and pIII, respectively). Interestingly, aberrant constitutive
MHCII expression occurs on some tumor cells such as melanoma
(Martins et al., 2007; Degenhardt et al., 2010). Despite this
restricted constitutive expression pattern, MHCII molecules are
inducible by IFN-γ in most cell types; a unique feature of
IFN-γ. The fact that MHCI and MHCII molecules are inducible
by cytokines is highly relevant to ErbB/HER signaling because
as outlined in more detail below, there are functional links
between cytokine signaling and ErbB/HER signaling. Moreover,
ErbB/HER signaling can also influence the expression of the TFs
that bind to the promoters of HLA class I genes such as NFκB
and IRF-1 (Andersen et al., 2008; Shostak and Chariot, 2015).
Thus, ErbB/HER signaling pathways are well poised to alter MHC
expression (positively or negatively) via mechanisms that are not
entirely understood.
MHC Molecules and Cancer
In the setting of cancer, MHC molecules play the pivotal
role of presenting processed tumor antigens to CD4 and CD8
lymphocytes in order to generate a tumor-specific cytotoxic
response (Seliger, 2008b; Hastings, 2013). As tumor antigens
are ultimately derived from self, barriers to the activation of an
antitumor T cell response exist intrinsically as T cells with affinity
for self-antigens are deleted during T cell development. Further,
tumor cells can create an immunosuppressive microenvironment
to suppress anti-tumor T cell responses (Kim et al., 2006). As
mentioned earlier, one mechanism through which tumor cells
evade detection by the immune system is the down regulation
of the surface expression of MHCI molecules. This can occur via
many mechanisms including the genetic loss of the MHC locus,
epigenetic silencing, and many others (Marincola et al., 2000;
Seliger, 2008a,b, 2014; van der Burg et al., 2016). Importantly,
while some of these defects are irreversible, others are not
and in these cases the expression of MHCI molecules can
be corrected or ‘rescued’ by cytokines (such as IFNs) and
medications such as metformin, inhibitors of DNA methylation,
histone deacetylase (HDAC) inhibitors, and other approaches
including targeted therapies as outlined later in this review
(Seliger and Pfizenmaier, 1989; Komatsu and Hayashi, 1998;
Magner et al., 2000; Lopez-Albaitero et al., 2006; Khan et al.,
2008; Han et al., 2011; Lampen and van Hall, 2011; Oliveras-
Ferraros et al., 2012). Many immune-based therapies hinge on the
generation of effector CD4 and/or CD8 T cells. As such, being
able to increase MHCI and/or MHCII levels pharmacologically
on tumor cells would be an attractive complement to CD4/CD8-
based immunotherapy because CD4- and CD8 T cell responses
are functionally influenced by the pMHC density present at the
cell surface. For MHCI, as pMHCI density is increased, T cell
activation becomes more efficient and the inhibition seen in the
setting of an excessively long TCR-pMHCI interaction half-life is
attenuated (Gonzalez et al., 2005). For MHCII, higher pMHCII
density can elicit a more robust CD4 T cell response than the
same pMHCII at a lower density (Vanguri et al., 2013). While it
is less clear if increases in pMHC density can functionally alter
an anti-tumor immune response, increasing pMHC density via
the aforementioned approaches offers another possible avenue to
manipulate interactions between tumor cells and therapeutic T
cells.
In addition to their level of expression, the peptides bound
to MHC molecules play a crucial role in anti-tumor immunity.
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As mentioned previously, the presentation of strongly antigenic
peptides (such as neoantigens derived from mutations) via
MHCI or MHCII can have an enormous impact on clinical
responses to immunotherapies such as those targeting immune
checkpoints (mediated by CTLA-4 signaling and the PD-
1/PD-L1 axis) (Lu and Robbins, 2016; Ward et al., 2016).
With this in mind, it will be crucial to understand how
oncogenic events and anti-cancer therapies influence antigen
processing, antigen presentation, and the pool of antigenic
peptides that can be displayed on the cell surface of tumors
via MHC molecules and detected by anti-tumor CD4- and/or
CD8 T lymphocytes (Chang and Ferrone, 2007; Hastings,
2013).
LINKING ERBB/HER TO THE MHC
Given their canonical roles in cancer biology and immunology,
respectively, it is not surprising that attempts to identify
interactions between the ErbB/HER and MHC molecules goes
back three decades (Schreiber et al., 1984). These initial papers
examined the ability of EGFR ligands to influence MHC
expression. For example, it was found that epidermal growth
factor (EGF) treatment could reduce the binding of KE-2
antibodies (which recognize an epitope on the heavy chain
of HLA class I molecules) to A431 cells; a finding that pre-
dates the seminal paper by Sporn and Roberts (1985) regarding
the autocrine secretion of growth factors such as TGF-α by
cancer cells (Schreiber et al., 1984; Sporn and Roberts, 1985).
In regards to MHCII, links between MHCII expression and
ErbB/HER ligands dates back over two decades where it was
demonstrated that the induction of HLA-DR molecules by
IFN could be attenuated by ErbB/HER ligands EGF and/or
transforming growth factor-α (TGFA) in thyroid epithelial cells
and keratinocytes (Lahat et al., 1992; Mitra and Nickoloff, 1992).
These early studies provided evidence that there were signals
initiated by EGFR activation that had a repressive effect on the
expression of MHCI and MHCII molecules at least in some
cellular contexts.
When considering ErbB/HER−MHC interactions, it is
important to consider the crosstalk that exists between ErbB/HER
receptors and members of the cytokine receptor superfamily
(Kaczmarski and Mufti, 1991; Prenzel et al., 2000). For example,
in response to cytokines such as IFN-γ that induce MHC
expression, ErbB/HER activation can occur via the protease-
dependent release of ErbB/HER ligands (Burova et al., 2007).
As a result, the cellular response to cytokines that induce
MHC molecules involves the activation of ErbB/HER receptors.
This places the EGFR and other members of the ErbB/HER
family, as well as those pathways downstream, in a unique
position to influence the cellular response to cytokines and thus
MHC induction. This becomes even more important when one
considers the dual nature of MHCI regulation described earlier
since malignant cells can harbor defects in constitutive MHCI
expression yet retain their responsiveness to cytokines. In such
a scenario, it is possible that oncogenic ErbB/MHC signaling
would be particularly impactful since MHCI expression on tumor
cells would be effectively dependent on cytokines present in the
tumor microenvironment for MHCI expression yet rendered less
responsive to cytokines due to aberrant ErbB/HER signaling.
ErbB/HER Ligands and MHC Expression
The ligands for ErbB/HER family members are EGF-family
growth factors that include EGF, TGFA, amphiregulin (AREG),
heparin-binding EGF-like growth factor (HBEGF), betacellulin
(BTC), epigen (EPGN), epiregulin (EREG), and four neuregulins
(NRG1-4; are also called heregulins) (Normanno et al., 2003a;
Schneider and Wolf, 2009). These ligands bind ErbB/HER
receptors with varying specificities and induce the formation
of homo- and heterodimers creating a large number of
possible receptor-ligand combinations (Table 3) (Roskoski,
2014). Through these interactions, ErbB/HER ligands initiate
signal transduction via complex signaling networks that lead
to large-scale changes in gene expression (Normanno et al.,
2006). ErbB/HER ligands are widely expressed in epithelial
tissues including those that give rise to the most common
forms of human cancer such as the skin, gut, lungs and the
aerodigestive tract. These ligands exert distinct effects based upon
the receptors they engage and the nature of the downstream
signals they transmit (O-Charoenrat et al., 2002; Zaiss et al.,
2015). For example, by activating different receptors, ligands
induce signals with distinct intensities and durations that in
turn contribute to ligand-specific effects on gene expression
(Nagashima et al., 2007). Moreover, ligands activating the same
ErbB/HER receptor bind with different affinities causing distinct
biological outcomes (Macdonald-Obermann and Pike, 2014).
Transgenic and knockout mouse models have demonstrated
these differences underscoring the fact that these ligands exert
distinct effects even within the same tissue context (Table 4)
(Normanno et al., 2006). In the skin, forced expression of
TGF-α causes papillomas at sites of mechanical irritation,
forced expression of AREG induces psoriatic-like lesions, and
forced expression of betacellulin causes altered hair development
(Vassar and Fuchs, 1991; Dominey et al., 1993; Cook et al., 1997;
Schneider et al., 2008). Knockout studies have also illustrated
the different roles for ErbB/HER ligands within the same tissue
as mice deficient in both EGF and TGF-α expression show
impaired prostate development while mice deficient only in TGF-
α show increased proliferation of prostate tissue compared to
wild-type (Abbott et al., 2003). This suggested that intact TGF-α
signaling is required to control EGF-stimulated proliferation
of prostate tissue. Similar observations were made in the
central and peripheral nervous systems where EGF, TGF-α, and
HBEGF are all expressed. Experiments in mice deficient in TGF-
α demonstrated normal development and functioning of the
peripheral nervous system suggesting EGF and HBEGF signaling
are sufficient and compensate for a lack of TGF-α deficient
signaling (Xian and Zhou, 2004). Despite the above phenotypes,
the impact of ErbB/HER ligands on adaptive immune responses
in these models are incompletely understood in part because
these ligands were initially characterized for their ability to
influence processes such as cell growth and survival. However,
recently there has been a growing appreciation for the immune
functions of ErbB/HER ligands.
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TABLE 3 | ErbB/HER receptors and their cognate ligands.
Ligands ERBB Family Members
EGFR/ ERBB1/ HER1 ERBB2/ HER2/ NEU ERBB3/ HER3 ERBB4/ HER4
EGF + No known ligands
Epigen (EPGN) +
Transforming growth factor-α (TGF-α) +
Amphiregulin (AREG) +
Betacellulin (BTC) + +
Heparin-binding epidermal growth + +
factor-like growth factor (HB-EGF)
Epiregulin (EREG) + +
Neuregulin/Heregulin 1 (Nrg1/Hrg1) + +
Neuregulin/Heregulin 2 (Nrg2/Hrg2) + +
Neuregulin/Heregulin 3 (Nrg3/Hrg3) +
Neuregulin/Heregulin 4 (Nrg4/Hrg4) +
TABLE 4 | Impact of ErbB/HER ligand knockout and overexpression.





TGF-α KO Eyes, hair, and skin Luetteke et al., 1999; Wong,
2003
AREG KO Mammary glands Luetteke et al., 1999
EGF, TGF-α, AREG KO Eyes, hair, skin, mammary Luetteke et al., 1999
EGF OE Infertile, growth retardation,
shortened small intestine
Erwin et al., 1999; Chan and
Wong, 2000; Wong et al., 2000
AREG OE Psoriasis-like dermatitis Cook et al., 1997
TGF-α OE Epithelial hyperplasia,
pancreatic metaplasia, breast
carcinoma
Jhappan et al., 1990; Sandgren
et al., 1990
One important role ErbB/HER ligands in the context
of adaptive immunity was recently uncovered when it was
demonstrated that regulatory T cells (T regs) express the EGFR
and respond to EGFR ligands such as amphiregulin (AREG)
(Zaiss et al., 2013). In addition, a role for AREG in ultraviolet
radiation (UVR)-mediated immunosuppression has recently
been reported (Meulenbroeks et al., 2015). The ability of immune
cells including CD4 and CD8 T cells to produce AREG further
underscores the expanding appreciation for the role of ErbB/HER
ligands in adaptive immune responses including those against
tumors (Zaiss et al., 2006; Kwong et al., 2010; Qi et al., 2012;
Burzyn et al., 2013). Despite these examples, the functional role
of ErbB/HER ligands in shaping anti-tumor immune responses
in vivo is poorly defined though the ability of these ligands to
influence the APM and MHC expression places them in a central
position to do so.
As mentioned above, in the 1980s and 1990s, several groups
found that treatment of cells with ErbB/HER ligands such as
EGF and TGFA repress the expression/induction of MHCI and
MHCII molecules (Schreiber et al., 1984; Lahat et al., 1992;
Mitra and Nickoloff, 1992). More recently, we have also shown
that EGF can repress the induction of MHCII molecules by
IFN-γ (Pollack et al., 2011). Likewise, others have shown similar
effects of ErbB/HER ligands. For example, in their studies on
esophageal and gastric cancer, Mimura et al. demonstrated that
MHCI was repressed by the neuregulin NRG-1-β1 (Mimura
et al., 2013). Likewise, in their studies on prostate cancer, Chen
et al. (2015) showed that EGF could repress MHCI expression.
However, in these and other studies, not all cells respond to
ErbB/HER ligands in the same manner; cells responding to
one ligand may fail to respond to another, and in some cells,
ErbB/HER ligands have no effect on MHC expression (Mimura
et al., 2013; Vantourout et al., 2014; Chen et al., 2015). Such
differences in the responses to ErbB/HER ligands are likely
due to the complex nature of ErbB/HER signaling and MHC
expression. For example, the cellular response to ErbB/HER
ligands depends on ErbB/HER expression patterns and is likely
influenced by the (activation) status of downstream enzymes
(such as RAS and RAF) and other proteins that impact the
TABLE 5 | Examples of ErbB/HER ligands repressing MHC expression.
ERBB/HER Ligand MHC Repressed Reference
EGF MHC class I Schreiber et al., 1984
EGF MHC class II Lahat et al., 1992
EGF/TGFA MHC class II Mitra and Nickoloff, 1992
EGF MHC class II Pollack et al., 2011
NRG-1-b1 MHC class I Mimura et al., 2013
EGF MHC class I Chen et al., 2015
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response to ErbB/HER inhibition (Gazdar, 2009). Moreover, as
mentioned earlier, when considering the impact of ErbB/HER
ligands on MHC expression both constitutive and inducible
MHCI expression warrant investigation as some effects may
require cytokine treatment(s) to be manifest. Table 5 provides a
summary of studies demonstrating repression of MHC molecules
by ErbB/HER ligands (in at least some contexts).
Further complicating the picture, especially as it relates
to ErbB/HER-MHCI interactions, is the fact that ErbB/HER
signaling activates pathways known to have opposing effects on
MHC expression. For example, ErbB/HER signaling can activate
NFκB, IRF-1, and Stat1, known positive regulators of MHC
expression, while at the same time activate the MAPK pathway
which can negatively regulate MHC expression (Figure 2)
(Pedersen et al., 2005; Andersen et al., 2008; van den Elsen,
2011; Mimura et al., 2013; Sapkota et al., 2013; Chen et al.,
2015; Shostak and Chariot, 2015). Therefore, the balance of these
positive and negative regulators of MHC expression induced
in response to ErbB/HER activation may ultimately dictate
their impact on MHC expression. The study by Mimura et al.
highlights this point. In their model, a clear hierarchy existed
as EGF failed to influence MHCI expression, whereas NRG-
1β1 repressed it and both the MAPK and PI3K pathways were
implicated in modulating MHCI expression (Mimura et al.,
2013). Thus, while many questions remain regarding the impact
of ErbB/HER ligands on the APM there is growing evidence
that in some contexts these ligands influence MHC expression.
Moreover, based upon the expression pattern of ErbB/HER
receptors present on a given tumor cell, some ligands may
influence MHC expression whereas others will not. Figure 2
illustrates some of the above concepts.
ErbB/HER Receptors, Inhibitors, and
MHC Expression
The four members of the ErbB/HER family include the EGFR
(also known as ErbB1 and HER1), ErbB2 [also known as HER2
and Neu, ErbB3 (HER3), and ErbB4 (HER4)] (Roskoski, 2014).
Structurally, these receptors contain an extracellular ligand-
binding domain, a transmembrane domain, and a cytoplasmic
domain that contains tyrosine kinase activity (Lemmon et al.,
2014). There are some noteworthy exceptions to the preceding
description. Namely, ErbB2/HER2/neu has no known ligand, and
ErbB3/HER3 has impaired tyrosine kinase activity. ErbB/HER
receptors can signal as homo- or heterodimers creating an array
of combinations that have distinct signaling outputs (Roskoski,
2014). Moreover, hierarchies exist such that the ErbB2/ErbB3
heterodimer is felt to be the most potent ErbB pairing signaling
combination (Pinkas-Kramarski et al., 1996; Tzahar et al., 1996;
Baselga and Swain, 2009). ErbB/HER receptors are widely
expressed on normal and malignant cell types (Salomon et al.,
1995). Genetic knockout of ErbB/HER receptors in mice leads
FIGURE 2 | Potential mechanisms relating ErbB/HER ligands, receptors, and MHC expression. ErbB/HER ligands bind and activate different ErbB/HER
receptors initiating distinct signal transduction pathways and cellular effects. As a result, there may be differences across ligand groups based upon the receptors
and downstream signaling pathways they activate. In addition, even ErbB/HER ligands that bind the same receptors can have distinct impacts on downstream
signaling and as such may have distinct effects on MHC expression. ErbB/HER ligands and receptors activate signaling pathways known to negatively (such as the
MAPK pathway), and positively (such as NFκB and IRF-1), regulate MHC expression via the binding of transcription factors (TFs) to MHC promoters or the promoters
of co-activators such as CIITA. As a result, in any given cellular context, the sum of these opposing effects will likely determine the impact of ErbB/HER activation
and inhibition on MHC expression.
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to alterations in numerous tissues (Table 6). In addition to
their classical roles in regulating cellular proliferation, survival,
angiogenesis, apoptosis, and the cell cycle, these receptors
have recently been implicated in the control of epithelial-
to-mesenchymal transition (EMT) (Chen et al., 2015). Thus,
ErbB/HER family members can regulate a variety of complex
processes including immune responses as outlined below.
Before reviewing the immune effects of ErbB/HER proteins,
it is worth highlighting the fact that these proteins have been
examined from markedly different yet valid perspectives (Seliger
and Kiessling, 2013). From the cancer biology perspective,
ErbB/HER proteins are canonical oncogenic enzymes that
drive tumor cell proliferation/survival/angiogenesis and
metastasis (Hynes and Lane, 2005). This perspective considered
little the immune effects of ErbB/HER proteins yet fueled
enormous efforts to inhibit ErbB/HER expression and/or activity
(Mendelsohn and Baselga, 2000; Normanno et al., 2003a).
Contrasting this view is the tumor immunology perspective
that considers ErbB/HER proteins as bonafide tumor antigens
(Zaks and Rosenberg, 1998; Nistico et al., 1999; Disis et al.,
2000). From this perspective, ErbB/HER-derived peptides
including those derived from activating mutations, such as the
EGFRvIII variant with a mutation in the extracellular domain
of the receptor, have the potential to stimulate an anti-tumor
immune response innately or via vaccination (Li and Wong,
2008; Nedergaard et al., 2012; Paff et al., 2014; Schneble et al.,
2014). Vaccine studies using a 14-amino acid peptide spanning
the mutated extracellular domain of EGFRvIII (CDX-110) fused
to adjuvant have shown durable oncogene-specific antibody
and CD8 T cell responses as well as improved survival in
glioblastoma multiforme patients (Sampson et al., 2008). In
this case, the expression of ErbB/HER proteins on tumor cells
would be required for successful anti-cancer therapy and by
targeting mutations specific to cancer cells these therapies result
in minimal bystander damage of healthy somatic cells expressing
normal ErbB/HER proteins. Other studies incorporate both
perspectives by investigating interactions between oncogenic
ErbB/HER proteins and proteins central to immune responses;
namely MHC molecules.
Attempts to establish links between the expression of
ErbB/HER family members and MHC molecules have been the
subject of study for many years (Nouri et al., 1995; Nistico et al.,
1997; Lollini et al., 1998). Using a forced-expression approach,
Herrmann et al. (2004) demonstrated that the expression of
ErbB2/HER2 was associated with decreases in MHCI and other
components of the APM. Complementing these findings using
siRNA-based approaches, Choudhury et al. (2004) demonstrated
that the loss of ErbB2/HER2 was associated with increases
in MHCI molecules. These studies provided links between
ErbB/HER proteins and MHC expression. The development
of pharmacologic ErbB/HER inhibitors has provided additional
evidence supporting interactions between ErbB/HER proteins
and MHC molecules.
Because MHC molecules govern interactions between tumor
cells and CD4 and CD8 T cells, early studies examined the
effects of ErbB/HER inhibition on MHC expression. In one
early study, no effect of the anti-HER monoclonal antibody
(mAb) trastuzumab on MHC expression was seen though
the treatment did enhance tumor lysis by MHCI-restricted
cytotoxic T lymphocytes (CTLs) (Kono et al., 2004). Our
group explored the impact of EGFR inhibitors on MHCI and
MHCII expression and found that small molecule tyrosine
kinase inhibitors (TKIs) (such as PD168393 and AG1478) as
well as the EGFR blocking antibody cetuximab (alone or with
the ErbB2/HER2/neu blocking antibody trastuzumab) could
enhance the induction of MHCI and MCHII molecules by
IFN-γ (Pollack et al., 2011). In some experimental models, the
addition of either PD168393 or cetuximab alone augmented
MHCI even in the absence of IFN-γ. Subsequent studies
have confirmed that at least under some circumstances
ErbB/HER inhibitors can enhance MHCI and/or MHCII
expression. For example, erlotinib, cetuximab and the pan
ErbB/HER inhibitor dacomitinib increased the induction of
MHCII molecules by IFN-γ in head and neck cancer cell
lines (Kumai et al., 2013, 2015). In their study on non-
small cell lung cancer, Okita et al. (2015) found that gefitinib
upregulated MHCI expression in some cellular contexts.
Moreover, anti-ErbB2/HER2/Neu therapy increased MHCII
TABLE 6 | Tissues altered by genetic knockout of ErbB/HER receptors
Receptor Tissues impacted by genetic
knockout
Reference
ErbB1/HER1/EGFR Epidermis, mammary gland, lung,
pancreas, gastrointestinal tract,
central and peripheral nervous
system, immune system (regulatory
T cells)
Miettinen et al., 1995; Sibilia and
Wagner, 1995; Threadgill et al., 1995;
Sibilia et al., 1998; Wiesen et al., 1999;
Normanno et al., 2003b
ErbB2/HER2/NEU Mammary gland, heart, central
nervous system
Lee et al., 1995; Xie et al., 1997; Jones
and Stern, 1999; Park et al., 2001;
Crone et al., 2002; Leu et al., 2003
ErbB3/HER3 Heart, central and peripheral
nervous system, mammary gland
Erickson et al., 1997; Troyer and Lee,
2001
ErbB4/HER4 Epidermis, mammary gland,
myocardium, central and peripheral
nervous system
Gassmann et al., 1995; Jones et al.,
1999; Golub et al., 2004
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levels in vivo (Mortenson et al., 2013). Further illustrating
relevant functional interactions between ErbB/HER inhibition
and MHC molecules was a study demonstrating that EGFRI
resistance is associated with defects in MHCI expression
(Garrido et al., 2014). The above studies illustrate that under
some contexts, ErbB/HER proteins and inhibitors thereof can
influence the expression of MHC molecules. Table 7 lists studies
reporting increases in MHCI and/or MHCII by ErbB/HER
inhibition.
While the above provide evidence that ErbB/HER activity
impacts MHC expression, it is important to note that just
as was the case for ErbB/HER ligands, not all cells respond
to ErbB/HER inhibition with increases in MHC expression.
We and others have shown that treatment of some cells
with inhibitors of ErbB/HER proteins does not alter MHC
expression (Pollack et al., 2011; Mimura et al., 2013; Okita
et al., 2015). Thus, in some cells, ErbB/HER activity is coupled
to MHC expression, whereas in other cells this is not the
case. While the mechanisms underpinning these interactions
are still being explored, some cells that are unresponsive to
ErbB/HER inhibition respond to inhibitors of downstream
enzymes particularly those inhibiting enzymes in the mitogen-
activated protein kinase (MAPK) pathway as outlined below and
shown in Figure 3.
ErbB/HER Downstream Signaling and
MHC Expression
ErbB/HER proteins are signaling hubs that can initiate signal
transduction via a variety of downstream pathways that include
the RAS/RAF/MAPK pathway, the phosphoinositide-3-kinase
(PI3K) pathway, the phospholipase C-γ (PLC-γ) pathway and
signal transducers and activators of transcription (STATS)
(Pines et al., 2010). Evidence for direct links between enzymes
downstream of ErbB/HER proteins, such as RAS, and the APM
have existed for over twenty years (Seliger et al., 1988, 1996,
1998; Seliger and Pfizenmaier, 1989; Lohmann et al., 1996). In
addition, links between RAS mutations and MHC expression
have been reported in colorectal carcinoma (Atkins et al., 2004).
More recently, inhibitors of the aforementioned pathways have
been exploited to examine interactions between these pathways
and MHC expression. Akin to the development of ErbB/HER
inhibitors, the main paradigm fueling the development these
inhibitors (such as those targeting BRAFV600E and MEK to
inhibit the MAPK pathway and those targeting the PI3K
pathway) centered on their potential to block proliferative
and survival signals rather than their immune effects (Rodon
et al., 2013; Zhao and Adjei, 2014; Sidaway, 2015; Thorpe
et al., 2015). Despite this, there is clear evidence that
inhibition of enzymes downstream of ErbB/HER receptors,
especially the MAPK pathway, alters MHC expression in some
contexts.
Early studies using pre-clinical MEK inhibitors (such as
PD98059) revealed that MEK inhibition augments MHCI and
MHCII expression (as well as CD86, CD80, and CD40) on
and allostimulation by growth factor-dependent DC in the
presence of TNF-α (Yanagawa et al., 2002). Likewise, another
group reported that PD98059 could increase MHCII expression
on monocyte-derived DCs (moDCs) (Aiba et al., 2003). These
studies provided early links between the MAPK pathway and
MHC expression in the context of professional APCs. As
mentioned earlier, similar to tumor cells, microbes such as Mtb
can down-regulate MHC expression to avoid detection by the
immune system. Mechanistically, the MAPK pathway has been
implicated since the down regulation of the MHCII master
regulator CIITA in macrophages by Mtb was mediated by MAPK
signaling and reversed by the MEK inhibitor U0126 (Pennini
et al., 2006). These observations support subsequent studies
demonstrating that MAPK inhibitors influence MHC expression
in the context of cancer.
TABLE 7 | Examples of ErbB/HER inhibitors augmenting MHC expression.
Inhibitor(s) Type of inhibitor Target(s) MHC molecule
increased
Reference





MHC class I and
MHC class II




EGFR/ErbB/1/HER1 MHC class I and
MHC class II
Zhou and Brattain, 2005;
Pollack et al., 2011
Cetuximab Blocking antibody EGFR/ErbB/1/HER1 MHC class I and
MHC class II
Pollack et al., 2011
Trastuzumab Blocking antibody ErbB2/HER2/neu MHC class I and
MHC class II





MHC class II Schaefer et al., 2007;
Kumai et al., 2013
Cetuximab Blocking antibody EGFR/ErbB1 MHC class II Kumai et al., 2013











MHC class I Hirata et al., 2005; Okita
et al., 2015
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FIGURE 3 | ErbB/HER downstream signaling pathways may influence the ability of ErbB/HER and other kinase inhibitors to modulate MHC
expression. In settings where the MAPK pathway is actively repressing MHC expression, the location of the activating/oncogenic event (indicated in red) will likely
influence the response to ErbB/HER and/or other kinase inhibitors. (A) In the setting of ErbB/HER ligand overproduction, inhibition of ErbB/HER activity (via an
ErbB/HER inhibitor) and/or enzymes in the MAPK signaling pathway may increase MHC expression. (B) In the setting of ErbB/HER activating mutations and/or
overproduction, an ErbB/HER inhibitor and/or MAPK inhibitor may increase MHC expression. (C) In the setting of an activating RAS mutation, the effect of an
ErbB/HER inhibitor may be null/minimal because MAPK signaling is being driven by activated RAS, whereas a downstream MAPK inhibitor may increase MHC
expression. (D) In the setting of an activating mutation in BRAF, as with an activating RAS mutation, an ErbB/HER inhibitor would not likely change MHC expression
whereas a BRAF inhibitor and/or a MEK inhibitor may increase MHC expression.
Kono and colleagues reported that the expression of
melanoma differentiation antigens (MDAs) increased in the
presence of U0126 and PD98059 (Kono et al., 2006). While
they found no effect on MHC expression, a subsequent study
by Sers et al. (2009) demonstrated that treatment of cells with
the MEK inhibitor U0126 led to increases in MHCI expression.
The FDA approval and clinical use of BRAFV600E and MEK
inhibitors (such as vemurafenib, dabrafenib, and trametinib) have
further underscored the immune effects of MAPK inhibition in
the context of cancer. For example, vemurafenib induced changes
in the expression of melanoma differentiation antigens (MDA),
and the tumor microenvironment in patients including increases
in CD8+ T cell infiltration (Boni et al., 2010; Frederick et al.,
2013). Again, in these studies, no changes in MHC expression
were seen, yet they underscored the potent immunologic effects
induced by disruption of oncogenic MAPK signaling.
Our group looked at the ability of vemurafenib to influence
the induction of MHCI and MHCII molecules by IFN-γ and
IFN-γ2b. We found that in BRAFV600E mutant melanoma
cell lines lacking wild type BRAF the induction of MHCI
and MHCII was enhanced in the presence of vemurafenib
at nanomolar concentrations and that basal levels of MHCI
decreased with the forced expression of BRAFV600E (Sapkota
et al., 2013). Further support identifying the MAPK pathway
(and phospho-ERK in particular) as a dominant regulator of
MHCI expression (in esophageal and gastric cancer) comes
from the study by Mimura and colleagues (Mimura et al.,
2013). More recently, others have reported increases in MHC
expression when oncogenic MAPK signaling is disrupted
especially in the context of cytokine treatment or adoptive
cell therapy (Mimura et al., 2013; Hu-Lieskovan et al., 2015;
Sabbatino et al., 2016; Whipple et al., 2016). Thus, inhibitors
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of MAPK signaling can influence the expression and induction
of MHC molecules in some settings through several possible
mechanisms as outlined below. Table 8 lists examples where
inhibitors of enzymes in the MAPK pathway increase MHC
expression.
One mechanism implicated in mediating MAPK-MHCII
interactions is through the activity of the MHCII co-activator
(and ‘master regulator’) CIITA. CIITA is critical to the generation
of immune responses as it is responsible for regulating the
expression of MHC class II molecules (Choi et al., 2011). CIITA
does not directly bind DNA, but instead regulates transcription
by interacting with TFs and elements of the enhanceosome
complex affecting chromatin remodeling and transcription
initiation (Reith and Boss, 2008; Devaiah and Singer, 2013). The
activity of CIITA is highly regulated through numerous post-
translational modifications including ubiquitination, acetylation,
and phosphorylation (Wu et al., 2009; Morgan et al., 2015). Early
work demonstrated that post-translational phosphorylation of
various serine residues of CIITA, were crucial to its ability to
localize to the nucleus and increase MHC II expression (Greer
et al., 2004). In this study, Greer and colleagues demonstrated
that the loss of these phosphorylation sites was associated with
an increase in the activation of endogenous MHCII genes. This
finding was subsequently confirmed using dominant negative
proteins and the ERK inhibitor PD98059 both of which increased
MHC II induction by CIITA by attenuating ERK activity (Voong
et al., 2008). Thus, while many questions remain, the MAPK
pathway likely impacts MHCII expression in part via changes in
CIITA post-translational modifications.
Compared to MHCII, the mechanisms through which MHCI
is regulated by MAPK signaling is less well defined. Analogous
to CIITA for MHCII, NLRC5/CITA has been shown to be a
key regulator of MHCI expression that has been implicated in
cancer (Meissner et al., 2010; Kobayashi and van den Elsen,
2012; Yoshihama et al., 2016). We have found that vemurafenib
increases in NLRC5/CITA mRNA induction by IFN-γ (Sapkota
et al., 2013). In addition to possible effects on NLRC5/CITA,
others have identified a novel gain-of-function activity of
BRAFV600E that directly targets MHCI protein for degradation
(Bradley et al., 2015). This study underscores the intimate links
that exist between oncogenes and MHC expression.
INCORPORATING INFORMATICS TO
HELP UNDERSTAND ERBB/HER – MHC
INTERACTIONS
Given the complex nature of oncogenic signaling and the
regulation of immune responses, many complementary
approaches need to be used in order to fully understand
how ErbB/HER oncogenic signal transduction influences the
expression of MHC molecules and the APM. These will likely
include biochemical studies, cell-based studies, murine models,
and a detailed analysis of human samples. While bioinformatics
approaches are integral to all of the aforementioned models,
they are particularly useful in the setting of large tumor tissue
databases (Cooper et al., 2015; Li et al., 2015). Having databases
containing genomic, transcriptomic, and proteomic information
provides an invaluable opportunity to characterize relationships
between genomic events and those relevant to immunity in the
context of human cancer (Rutledge et al., 2013; Saba et al., 2015).
An example relevant to MHCI expression and regulation in
human cancer is outlined below.
NLRC5/CITA was known to be an important regulator of
MHCI molecules, yet until recently, its role in the setting of
human cancer was poorly defined. In a recently published study
by Yoshihama and colleagues, our understanding of the role of
NLRC5 in human cancer was greatly expanded (Yoshihama et al.,
2016). The authors in this study included bioinformatics-based
approaches to assess the expression pattern of NLRC5/CITA
and MHCI in human cancer thereby providing a much better
understanding of how NLRC5/CITA expression correlates with
other immune parameters in the setting of human tumors.
Moreover, these authors used this approach to determine that
expression of NLRC5/CITA correlated with survival in several
cancer types including melanoma, rectal cancer, bladder cancer,
uterine cancer, cervical cancer and head/neck cancer. This study
illustrates how genetic information from human tumor databases
can be combined with bioinformatics to generate clinically
relevant information. A brief description of some of these
resources and approaches are reviewed in the next paragraph.
A number of public bioinformatics resources exist to
investigate the relationship between immune parameters,
oncogenic driver mutations and signaling network activation.
TABLE 8 | Inhibition of enzymes in the MAPK pathway enhancing MHC expression
Inhibitor(s) Enzyme inhibited MHC molecule increased Reference
PD98059 MEK1MEK2 MHC class I and MHC class II Yanagawa et al., 2002
PD98059 MEK1MEK2 MHC class II Aiba et al., 2003
U0126 MEK1MEK2 MHC class I Sers et al., 2009
Vemurafenib BRAFV600E MHC class I and MHC class II Sapkota et al., 2013
PD98059 MEK1MEK2 MHC class I Mimura et al., 2013
Dabrafenib BRAFV600E MHC class I Hu-Lieskovan et al., 2015
Trametinib MEK1MEK2 MHC class I Hu-Lieskovan et al., 2015
Vemurafenib BRAFV600E MHC class I Sabbatino et al., 2016
Vemurafenib BRAFV600E MHC class I Whipple et al., 2016
U0126 MEK1MEK2 MHC class I Whipple et al., 2016
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The Cancer Genome Atlas1 is a public data resource of the
National Cancer Institute that has produced comprehensive
genomic, epigenomic, transcriptomic, and proteomic profiles
of over 11,000 patients with 33 distinct cancer types. The
data generated by TCGA is readily accessible via a number
of stand-alone public resources that facilitate exploration of
mutational spectra and copy number events, gene expression and
their relationship to clinical outcomes including the cBioPortal2,
the Broad Institute Tumor Portal3, and the Cancer Regulome
Explorer4(Cerami et al., 2012; Gao et al., 2013; Lawrence et al.,
2014). The use of these resources and others will provide
important avenues to examine interactions between ErbB/HER
ligands, receptors, and the APM to understand interactions
between these important oncogenes and adaptive immune
responses in a more comprehensive manner.
CONCLUSION
In summary, functional links between ErbB/HER ligands,
receptors, and MHC molecules demonstrates the intimate
connections that can exist between oncogenes and genes that
regulate antigen processing and presentation. The clinical use





define these relationships in more depth and to gain insight
into how signaling pathways defined for their role in cancer
influence fundamental immunologic processes. This information
will enhance our ability to use targeted therapies with more
insight and more rationally combine them with immune-based
therapies.
AUTHOR CONTRIBUTIONS
AK, drafting and conception of the review; MS, critical feedback
for the review; LC, drafting and conception of the review; HK,
critical feedback for the review; BP, conception, drafting, and final
approval of the review.
FUNDING
BP receives funding from the Winship Cancer Institute Skin
Cancer and Melanoma Fund, a Career Development Award from
the Melanoma Research Foundation, and a Merit Review Award
from the Department of Veterans Affairs.
ACKNOWLEDGMENT
The authors’ appreciated the comments and feedback by Michael
Rossi.
REFERENCES
Abbott, B. D., Lin, T. M., Rasmussen, N. T., Albrecht, R. M., Schmid, J. E., and
Peterson, R. E. (2003). Lack of expression of EGF and TGF-alpha in the fetal
mouse alters formation of prostatic epithelial buds and influences the response
to TCDD. Toxicol. Sci. 76, 427–436. doi: 10.1093/toxsci/kfg238
Accolla, R. S., Lombardo, L., Abdallah, R., Raval, G., Forlani, G., and Tosi, G.
(2014). Boosting the MHC class II-restricted tumor antigen presentation to
CD4+ T helper cells: a critical issue for triggering protective immunity and
Re-orienting the tumor microenvironment toward an anti-tumor state. Front.
Oncol. 4:32. doi: 10.3389/fonc.2014.00032
Aiba, S., Manome, H., Nakagawa, S., Mollah, Z. U., Mizuashi, M., Ohtani, T.,
et al. (2003). p38 Mitogen-activated protein kinase and extracellular signal-
regulated kinases play distinct roles in the activation of dendritic cells by
two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J. Invest.
Dermatol. 120, 390–399. doi: 10.1046/j.1523-1747.2003.12065.x
Al-Kasspooles, M., Moore, J. H., Orringer, M. B., and Beer, D. G. (1993).
Amplification and over-expression of the EGFR and erbB-2 genes in
human esophageal adenocarcinomas. Int. J. Cancer 54, 213–219. doi:
10.1002/ijc.2910540209
Andersen, P., Pedersen, M. W., Woetmann, A., Villingshoj, M., Stockhausen, M. T.,
Odum, N., et al. (2008). EGFR induces expression of IRF-1 via STAT1 and
STAT3 activation leading to growth arrest of human cancer cells. Int. J. Cancer
122, 342–349. doi: 10.1002/ijc.23109
Atkins, D., Breuckmann, A., Schmahl, G. E., Binner, P., Ferrone, S.,
Krummenauer, F., et al. (2004). MHC class I antigen processing pathway
defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer
109, 265–273. doi: 10.1002/ijc.11681
Baselga, J., and Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and
discovering ERBB3. Nat. Rev. Cancer 9, 463–475. doi: 10.1038/nrc2656
Beckhardt, R. N., Kiyokawa, N., Xi, L., Liu, T. J., Hung, M. C., El-Naggar,
A. K., et al. (1995). HER-2/neu oncogene characterization in head and neck
squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 121, 1265–1270.
doi: 10.1001/archotol.1995.01890110041008
Blair, J. A., Rauh, D., Kung, C., Yun, C. H., Fan, Q. W., Rode, H., et al. (2007).
Structure-guided development of affinity probes for tyrosine kinases using
chemical genetics. Nat. Chem. Biol. 3, 229–238. doi: 10.1038/nchembio866
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M.,
et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of
melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219.
doi: 10.1158/0008-5472.CAN-10-0118
Bradley, S. D., Chen, Z., Melendez, B., Talukder, A., Khalili, J. S., Rodriguez-
Cruz, T., et al. (2015). BRAFV600E Co-opts a conserved MHC class I
internalization pathway to diminish antigen presentation and CD8+ T-cell
recognition of Melanoma. Cancer Immunol. Res. 3, 602–609. doi: 10.1158/2326-
6066.CIR-15-0030
Burova, E., Vassilenko, K., Dorosh, V., Gonchar, I., and Nikolsky, N.
(2007). Interferon gamma-dependent transactivation of epidermal growth
factor receptor. FEBS Lett. 581, 1475–1480. doi: 10.1016/j.febslet.2007.
03.002
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., et al.
(2013). A special population of regulatory T cells potentiates muscle repair. Cell
155, 1282–1295. doi: 10.1016/j.cell.2013.10.054
Canueto, J., Cardenoso, E., Garcia, J. L., Santos-Briz, A., Castellanos-Martin, A.,
Fernandez-Lopez, E., et al. (2016). EGFR expression is associated with
poor outcome in cutaneous squamous cell carcinoma. Br. J. Dermatol. doi:
10.1111/bjd.14936 [Epub ahead of print].
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K.,
et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA 295, 2492–2502. doi: 10.1001/jama.295.21.2492
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al.
(2012). The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2, 401–404. doi:
10.1158/2159-8290.CD-12-0095
Frontiers in Pharmacology | www.frontiersin.org 12 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 13
Kersh et al. ErbB/HER Signaling and MHC Expression
Chan, S. Y., and Wong, R. W. (2000). Expression of epidermal growth factor in
transgenic mice causes growth retardation. J. Biol. Chem. 275, 38693–38698.
doi: 10.1074/jbc.M004189200
Chang, C. C., and Ferrone, S. (2007). Immune selective pressure and HLA class
I antigen defects in malignant lesions. Cancer Immunol. Immunother. 56,
227–236. doi: 10.1007/s00262-006-0183-1
Chen, X. H., Liu, Z. C., Zhang, G., Wei, W., Wang, X. X., Wang, H., et al. (2015).
TGF-beta and EGF induced HLA-I downregulation is associated with epithelial-
mesenchymal transition (EMT) through upregulation of snail in prostate cancer
cells. Mol. Immunol. 65, 34–42. doi: 10.1016/j.molimm.2014.12.017
Choi, K., Creighton, C. J., Stivers, D., Fujimoto, N., and Kurie, J. M.
(2007). Transcriptional profiling of non-small cell lung cancer cells
with activating EGFR somatic mutations. PLoS ONE 2:e1226. doi:
10.1371/journal.pone.0001226
Choi, N. M., Majumder, P., and Boss, J. M. (2011). Regulation of major
histocompatibility complex class II genes. Curr. Opin. Immunol. 23, 81–87. doi:
10.1016/j.coi.2010.09.007
Choma, M. K., Lumb, J., Kozik, P., and Robinson, M. S. (2015). A genome-wide
screen for machinery involved in downregulation of MHC class I by HIV-1 Nef.
PLoS ONE 10:e0140404. doi: 10.1371/journal.pone.0140404
Choudhury, A., Charo, J., Parapuram, S. K., Hunt, R. C., Hunt, D. M., Seliger, B.,
et al. (2004). Small interfering RNA (siRNA) inhibits the expression of the
Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu
positive tumor cell lines. Int. J. Cancer 108, 71–77. doi: 10.1002/ijc.11497
Comber, J. D., and Philip, R. (2014). MHC class I antigen presentation and
implications for developing a new generation of therapeutic vaccines. Ther.
Adv. Vaccines 2, 77–89. doi: 10.1177/2051013614525375
Concha-Benavente, F., Srivastava, R., Ferrone, S., and Ferris, R. L. (2016).
Immunological and clinical significance of HLA class I antigen processing
machinery component defects in malignant cells. Oral Oncol. 58, 52–58. doi:
10.1016/j.oraloncology.2016.05.008
Cook, P. W., Piepkorn, M., Clegg, C. H., Plowman, G. D., Demay, J. M.,
Brown, J. R., et al. (1997). Transgenic expression of the human amphiregulin
gene induces a psoriasis-like phenotype. J. Clin. Invest. 100, 2286–2294. doi:
10.1172/JCI119766
Cooper, L. A., Kong, J., Gutman, D. A., Dunn, W. D., Nalisnik, M., and Brat,
D. J. (2015). Novel genotype-phenotype associations in human cancers enabled
by advanced molecular platforms and computational analysis of whole slide
images. Lab. Invest. 95, 366–376. doi: 10.1038/labinvest.2014.153
Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002).
ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8,
459–465. doi: 10.1038/nm0502-459
Degenhardt, Y., Huang, J., Greshock, J., Horiates, G., Nathanson, K., Yang, X.,
et al. (2010). Distinct MHC gene expression patterns during progression of
melanoma. Genes Chromosomes Cancer 49, 144–154. doi: 10.1002/gcc.20728
DeSandro, A., Nagarajan, U. M., and Boss, J. M. (1999). The bare lymphocyte
syndrome: molecular clues to the transcriptional regulation of major
histocompatibility complex class II genes. Am. J. Hum. Genet. 65, 279–286. doi:
10.1086/302519
Devaiah, B. N., and Singer, D. S. (2013). CIITA and its dual roles in
MHC gene transcription. Front. Immunol. 4:476. doi: 10.3389/fimmu.2013.
00476
Disis, M. L., Knutson, K. L., Schiffman, K., Rinn, K., and Mcneel, D. G. (2000).
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with
HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat.
62, 245–252. doi: 10.1023/A:1006438507898
Dominey, A. M., Wang, X. J., King, L. E. Jr., Nanney, L. B., Gagne,
T. A., Sellheyer, K., et al. (1993). Targeted overexpression of transforming
growth factor alpha in the epidermis of transgenic mice elicits hyperplasia,
hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth Differ. 4,
1071–1082.
Erickson, S. L., O’shea, K. S., Ghaboosi, N., Loverro, L., Frantz, G., Bauer, M.,
et al. (1997). ErbB3 is required for normal cerebellar and cardiac development:
a comparison with ErbB2-and heregulin-deficient mice. Development 124,
4999–5011.
Erwin, C. R., Helmrath, M. A., Shin, C. E., Falcone, RA Jr, Stern, L. E., and Warner,
B. W. (1999). Intestinal overexpression of EGF in transgenic mice enhances
adaptation after small bowel resection. Am. J. Physiol. 277, G533–G540.
Falck, V. G., and Gullick, W. J. (1989). c-erbB-2 oncogene product staining
in gastric adenocarcinoma. An immunohistochemical study. J. Pathol, 159,
107–111.
Ferris, R. L., Whiteside, T. L., and Ferrone, S. (2006). Immune escape associated
with functional defects in antigen-processing machinery in head and neck
cancer. Clin. Cancer Res. 12, 3890–3895. doi: 10.1158/1078-0432.CCR-05-2750
Fortier, M. H., Caron, E., Hardy, M. P., Voisin, G., Lemieux, S., Perreault, C., et al.
(2008). The MHC class I peptide repertoire is molded by the transcriptome.
J. Exp. Med. 205, 595–610. doi: 10.1084/jem.20071985
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone,
C. R., et al. (2013). BRAF inhibition is associated with enhanced melanoma
antigen expression and a more favorable tumor microenvironment in patients
with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231. doi: 10.1158/1078-
0432.CCR-12-1630
Frederick, L., Wang, X. Y., Eley, G., and James, C. D. (2000). Diversity
and frequency of epidermal growth factor receptor mutations in human
glioblastomas. Cancer Res. 60, 1383–1387.
Galluzzi, L., Senovilla, L., Zitvogel, L., and Kroemer, G. (2012). The secret ally:
immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11, 215–233.
doi: 10.1038/nrd3626
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., et al.
(2013). Integrative analysis of complex cancer genomics and clinical profiles
using the cBioPortal. Sci. Signal. 6, pl1. doi: 10.1126/scisignal.2004088
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., and
Van Hall, T. (2016). The urgent need to recover MHC class I in
cancers for effective immunotherapy. Curr. Opin. Immunol. 39, 44–51. doi:
10.1016/j.coi.2015.12.007
Garrido, F., Cabrera, T., and Aptsiauri, N. (2010). “Hard” and “soft” lesions
underlying the HLA class I alterations in cancer cells: implications for
immunotherapy. Int. J. Cancer 127, 249–256. doi: 10.1002/ijc.25270
Garrido, G., Rabasa, A., Garrido, C., Lopez, A., Chao, L., Garcia-Lora, A. M., et al.
(2014). Preclinical modeling of EGFR-specific antibody resistance: oncogenic
and immune-associated escape mechanisms. Oncogene 33, 3129–3139. doi:
10.1038/onc.2013.288
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., et al. (1995).
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin
receptor. Nature 378, 390–394. doi: 10.1038/378390a0
Gazdar, A. F. (2009). Activating and resistance mutations of EGFR in non-small-
cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Oncogene 28(Suppl. 1), S24–S31. doi: 10.1038/onc.2009.198
Gobin, S. J., Van Zutphen, M., Westerheide, S. D., Boss, J. M., and Van Den Elsen,
P. J. (2001). The MHC-specific enhanceosome and its role in MHC class I and
beta(2)-microglobulin gene transactivation. J. Immunol. 167, 5175–5184. doi:
10.4049/jimmunol.167.9.5175
Golub, M. S., Germann, S. L., and Lloyd, K. C. (2004). Behavioral characteristics
of a nervous system-specific erbB4 knock-out mouse. Behav. Brain Res. 153,
159–170. doi: 10.1016/j.bbr.2003.11.010
Gonzalez, P. A., Carreno, L. J., Coombs, D., Mora, J. E., Palmieri, E., Goldstein, B.,
et al. (2005). T cell receptor binding kinetics required for T cell activation
depend on the density of cognate ligand on the antigen-presenting cell. Proc.
Natl. Acad. Sci. U.S.A. 102, 4824–4829. doi: 10.1073/pnas.0500922102
Grandis, J. R., and Tweardy, D. J. (1993). Elevated levels of transforming growth
factor alpha and epidermal growth factor receptor messenger RNA are early
markers of carcinogenesis in head and neck cancer. Cancer Res. 53, 3579–3584.
Greer, S. F., Harton, J. A., Linhoff, M. W., Janczak, C. A., Ting, J. P., and Cressman,
D. E. (2004). Serine residues 286, 288, and 293 within the CIITA: a mechanism
for down-regulating CIITA activity through phosphorylation. J. Immunol. 173,
376–383. doi: 10.4049/jimmunol.173.1.376
Han, W., Pan, H., Jiang, L., Wei, K., Zou, D., and Zhang, Z. (2011). A novel
approach to rescue immune escape in oral squamous cell carcinoma: Combined
use of interferon-gamma and LY294002. Oncol. Rep. 25, 181–187.
Hastings, K. T. (2013). GILT: shaping the MHC class II-restricted peptidome
and CD4(+) T cell-mediated immunity. Front. Immunol. 4:429. doi:
10.3389/fimmu.2013.00429
Herrmann, F., Lehr, H. A., Drexler, I., Sutter, G., Hengstler, J., Wollscheid, U.,
et al. (2004). HER-2/neu-mediated regulation of components of the MHC class
I antigen-processing pathway. Cancer Res. 64, 215–220. doi: 10.1158/0008-
5472.CAN-2522-2
Frontiers in Pharmacology | www.frontiersin.org 13 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 14
Kersh et al. ErbB/HER Signaling and MHC Expression
Hirata, A., Hosoi, F., Miyagawa, M., Ueda, S., Naito, S., Fujii, T., et al. (2005).
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3
heterodimer formation in lung cancer cells. Cancer Res. 65, 4253–4260. doi:
10.1158/0008-5472.CAN-04-2748
Hofmann, M., Stoss, O., Shi, D., Buttner, R., Van De Vijver, M., Kim, W.,
et al. (2008). Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology 52, 797–805. doi: 10.1111/j.1365-
2559.2008.03028.x
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries,
L. A., et al. (2014). US incidence of breast cancer subtypes defined by joint
hormone receptor and HER2 status. J. Natl. Cancer Inst. 106, dju055. doi:
10.1093/jnci/dju055
Huang, H. E., Chin, S. F., Ginestier, C., Bardou, V. J., Adelaide, J., Iyer,
N. G., et al. (2004). A recurrent chromosome breakpoint in breast cancer
at the NRG1/neuregulin 1/heregulin gene. Cancer Res. 64, 6840–6844. doi:
10.1158/0008-5472.CAN-04-1762
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L.,
et al. (2015). Improved antitumor activity of immunotherapy with BRAF and
MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241. doi:
10.1126/scitranslmed.aaa4691
Hynes, N. E., and Lane, H. A. (2005). ERBB receptors and cancer: the complexity
of targeted inhibitors. Nat. Rev. Cancer 5, 341–354. doi: 10.1038/nrc1609
Jhappan, C., Stahle, C., Harkins, R. N., Fausto, N., Smith, G. H., and Merlino, G. T.
(1990). TGF alpha overexpression in transgenic mice induces liver neoplasia
and abnormal development of the mammary gland and pancreas. Cell 61,
1137–1146. doi: 10.1016/0092-8674(90)90076-Q
Jones, F. E., and Stern, D. F. (1999). Expression of dominant-negative ErbB2 in the
mammary gland of transgenic mice reveals a role in lobuloalveolar development
and lactation. Oncogene 18, 3481–3490. doi: 10.1038/sj.onc.1202698
Jones, F. E., Welte, T., Fu, X. Y., and Stern, D. F. (1999). ErbB4 signaling in
the mammary gland is required for lobuloalveolar development and Stat5
activation during lactation. J. Cell Biol. 147, 77–88. doi: 10.1083/jcb.147.1.77
Kaczmarski, R. S., and Mufti, G. J. (1991). The cytokine receptor superfamily. Blood
Rev. 5, 193–203. doi: 10.1016/0268-960X(91)90036-C
Kelderman, S., Schumacher, T. N., and Kvistborg, P. (2015). Mismatch repair-
deficient cancers are targets for anti-PD-1 therapy. Cancer Cell 28, 11–13. doi:
10.1016/j.ccell.2015.06.012
Khan, A. N., Gregorie, C. J., and Tomasi, T. B. (2008). Histone deacetylase
inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen
presentation by melanoma cells. Cancer Immunol. Immunother. 57, 647–654.
Kim, R., Emi, M., Tanabe, K., and Arihiro, K. (2006). Tumor-driven evolution of
immunosuppressive networks during malignant progression. Cancer Res. 66,
5527–5536. doi: 10.1158/0008-5472.CAN-05-4128
Kobayashi, K. S., and van den Elsen, P. J. (2012). NLRC5: a key regulator of MHC
class I-dependent immune responses. Nat. Rev. Immunol. 12, 813–820. doi:
10.1038/nri3339
Komatsu, Y., and Hayashi, H. (1998). Histone deacetylase inhibitors up-regulate
the expression of cell surface MHC class-I molecules in B16/BL6 cells. J Antibiot.
(Tokyo) 51, 89–91. doi: 10.7164/antibiotics.51.89
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H.,
et al. (2004). Trastuzumab (Herceptin) enhances class I-restricted antigen
presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin.
Cancer Res. 10, 2538–2544. doi: 10.1158/1078-0432.CCR-03-0424
Kono, M., Dunn, I. S., Durda, P. J., Butera, D., Rose, L. B., Haggerty, T. J.,
et al. (2006). Role of the mitogen-activated protein kinase signaling pathway
in the regulation of human melanocytic antigen expression. Mol. Cancer Res. 4,
779–792. doi: 10.1158/1541-7786.MCR-06-0077
Kotekar, A. S., Weissman, J. D., Gegonne, A., Cohen, H., and Singer, D. S. (2008).
Histone modifications, but not nucleosomal positioning, correlate with major
histocompatibility complex class I promoter activity in different tissues in vivo.
Mol. Cell. Biol. 28, 7323–7336. doi: 10.1128/MCB.00889-08
Kumai, T., Matsuda, Y., Oikawa, K., Aoki, N., Kimura, S., Harabuchi, Y.,
et al. (2013). EGFR inhibitors augment antitumour helper T-cell responses
of HER family-specific immunotherapy. Br. J. Cancer 109, 2155–2166. doi:
10.1038/bjc.2013.577
Kumai, T., Ohkuri, T., Nagato, T., Matsuda, Y., Oikawa, K., Aoki, N., et al. (2015).
Targeting HER-3 to elicit antitumor helper T cells against head and neck
squamous cell carcinoma. Sci. Rep. 5:16280. doi: 10.1038/srep16280
Kwong, B. Y., Roberts, S. J., Silberzahn, T., Filler, R. B., Neustadter, J. H., Galan, A.,
et al. (2010). Molecular analysis of tumor-promoting CD8+ T cells in two-stage
cutaneous chemical carcinogenesis. J. Invest. Dermatol. 130, 1726–1736. doi:
10.1038/jid.2009.362
Lahat, N., Sheinfeld, M., Sobel, E., Kinarty, A., and Kraiem, Z. (1992). Divergent
effects of cytokines on human leukocyte antigen-DR antigen expression of
neoplastic and non-neoplastic human thyroid cells. Cancer 69, 1799–1807. doi:
10.1002/1097-0142(19920401)69:7<1799::AID-CNCR2820690723>3.0.CO;2-
8
Lampen, M. H., and van Hall, T. (2011). Strategies to counteract MHC-I defects in
tumors. Curr. Opin. Immunol. 23, 293–298. doi: 10.1016/j.coi.2010.12.005
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A.,
Golub, T. R., et al. (2014). Discovery and saturation analysis of cancer genes
across 21 tumour types. Nature 505, 495–501. doi: 10.1038/nature12912
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et al.
(2015). PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J.
Med. 372, 2509–2520. doi: 10.1056/NEJMoa1500596
Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., and Hauser, C. (1995).
Requirement for neuregulin receptor erbB2 in neural and cardiac development.
Nature 378, 394–398. doi: 10.1038/378394a0
Lei, S., Appert, H. E., Nakata, B., Domenico, D. R., Kim, K., and Howard, J. M.
(1995). Overexpression of HER2/neu oncogene in pancreatic cancer correlates
with shortened survival. Int. J. Pancreatol. 17, 15–21.
Lemmon, M. A., Schlessinger, J., and Ferguson, K. M. (2014). The EGFR family:
not so prototypical receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol.
6, a020768. doi: 10.1101/cshperspect.a020768
Leu, M., Bellmunt, E., Schwander, M., Farinas, I., Brenner, H. R., and
Muller, U. (2003). Erbb2 regulates neuromuscular synapse formation and is
essential for muscle spindle development. Development 130, 2291–2301. doi:
10.1242/dev.00447
Li, G., and Wong, A. J. (2008). EGF receptor variant III as a target
antigen for tumor immunotherapy. Expert Rev. Vaccines 7, 977–985. doi:
10.1586/14760584.7.7.977
Li, M. M., Monzon, F. A., Biegel, J. A., Jobanputra, V., Laffin, J. J.,
Levy, B., et al. (2015). A multicenter, cross-platform clinical validation
study of cancer cytogenomic arrays. Cancer Genet. 208, 525–536. doi:
10.1016/j.cancergen.2015.08.002
Lohmann, S., Wollscheid, U., Huber, C., and Seliger, B. (1996). Multiple levels
of MHC class I down-regulation by ras oncogenes. Scand. J. Immunol. 43,
537–544. doi: 10.1046/j.1365-3083.1996.d01-73.x
Lollini, P. L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E.,
et al. (1998). Down regulation of major histocompatibility complex class I
expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J.
Cancer 77, 937–941. doi: 10.1002/(SICI)1097-0215(19980911)77:6<937::AID-
IJC24>3.3.CO;2-O
Lopez-Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W., Deleo,
A. B., et al. (2006). Role of antigen-processing machinery in the in vitro
resistance of squamous cell carcinoma of the head and neck cells to recognition
by CTL. J. Immunol. 176, 3402–3409. doi: 10.4049/jimmunol.176.6.3402
Lu, Y. C., and Robbins, P. F. (2016). Targeting neoantigens for cancer
immunotherapy. Int. Immunol. 28, 365–370. doi: 10.1093/intimm/dxw026
Luetteke, N. C., Qiu, T. H., Fenton, S. E., Troyer, K. L., Riedel, R. F., Chang, A.,
et al. (1999). Targeted inactivation of the EGF and amphiregulin genes reveals
distinct roles for EGF receptor ligands in mouse mammary gland development.
Development 126, 2739–2750.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A.,
Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth
factor receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib. N. Engl. J. Med. 350, 2129–2139. doi: 10.1056/NEJMoa040938
Macdonald-Obermann, J. L., and Pike, L. J. (2014). Different epidermal growth
factor (EGF) receptor ligands show distinct kinetics and biased or partial
agonism for homodimer and heterodimer formation. J. Biol. Chem. 289, 26178–
26188. doi: 10.1074/jbc.M114.586826
Frontiers in Pharmacology | www.frontiersin.org 14 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 15
Kersh et al. ErbB/HER Signaling and MHC Expression
Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C.,
et al. (2000). Activation of MHC class I, II, and CD40 gene expression by histone
deacetylase inhibitors. J. Immunol. 165, 7017–7024.
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., and Ferrone, S. (2000). Escape
of human solid tumors from T-cell recognition: molecular mechanisms and
functional significance. Adv. Immunol. 74, 181–273. doi: 10.1016/S0065-
2776(08)60911-6
Martins, I., Deshayes, F., Baton, F., Forget, A., Ciechomska, I., Sylla, K., et al. (2007).
Pathologic expression of MHC class II is driven by mitogen-activated protein
kinases. Eur. J. Immunol. 37, 788–797. doi: 10.1002/eji.200636620
Meden, H., and Kuhn, W. (1997). Overexpression of the oncogene c-erbB-2
(HER2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol.
Reprod. Biol. 71, 173–179. doi: 10.1016/S0301-2115(96)02630-9
Meissner, T. B., Li, A., Biswas, A., Lee, K. H., Liu, Y. J., Bayir, E., et al. (2010). NLR
family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc.
Natl. Acad. Sci. U.S.A. 107, 13794–13799. doi: 10.1073/pnas.1008684107
Meissner, T. B., Liu, Y. J., Lee, K. H., Li, A., Biswas, A., Van Eggermond, M. C.,
et al. (2012). NLRC5 cooperates with the RFX transcription factor complex
to induce MHC class I gene expression. J. Immunol. 188, 4951–4958. doi:
10.4049/jimmunol.1103160
Mendelsohn, J., and Baselga, J. (2000). The EGF receptor family as targets for
cancer therapy. Oncogene 19, 6550–6565. doi: 10.1038/sj.onc.1204082
Meulenbroeks, C., Van Weelden, H., Schwartz, C., Voehringer, D., Redegeld, F. A.,
Rutten, V. P., et al. (2015). Basophil-derived amphiregulin is essential for UVB
irradiation-induced immune suppression. J. Invest. Dermatol. 135, 222–228.
doi: 10.1038/jid.2014.329
Miettinen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z., et al.
(1995). Epithelial immaturity and multiorgan failure in mice lacking epidermal
growth factor receptor. Nature 376, 337–341. doi: 10.1038/376337a0
Mimura, K., Shiraishi, K., Mueller, A., Izawa, S., Kua, L. F., So, J., et al.
(2013). The MAPK pathway is a predominant regulator of HLA-A expression
in esophageal and gastric cancer. J. Immunol. 191, 6261–6272. doi:
10.4049/jimmunol.1301597
Mitra, R. S., and Nickoloff, B. J. (1992). Epidermal growth factor and transforming
growth factor-alpha decrease gamma interferon receptors and induction of
intercellular adhesion molecule (ICAM-1) on cultured keratinocytes. J. Cell.
Physiol. 150, 264–268. doi: 10.1002/jcp.1041500207
Morgan, J. E., Shanderson, R. L., Boyd, N. H., Cacan, E., and Greer, S. F. (2015). The
class II transactivator (CIITA) is regulated by post-translational modification
cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63
ubiquitination. Biosci. Rep. 35:e00233. doi: 10.1042/BSR20150091
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di
Nicolantonio, F., et al. (2005). Gene copy number for epidermal growth
factor receptor (EGFR) and clinical response to antiEGFR treatment in
colorectal cancer: a cohort study. Lancet Oncol. 6, 279–286. doi: 10.1016/S1470-
2045(05)70102-9
Mortenson, E. D., Park, S., Jiang, Z., Wang, S., and Fu, Y. X. (2013). Effective anti-
neu-initiated antitumor responses require the complex role of CD4+ T cells.
Clin. Cancer Res. 19, 1476–1486. doi: 10.1158/1078-0432.CCR-12-2522
Nagashima, T., Oyama, M., Kozuka-Hata, H., Yumoto, N., Sakaki, Y., and
Hatakeyama, M. (2008). Phosphoproteome and transcriptome analyses of ErbB
ligand-stimulated MCF-7 cells. Cancer Genomics Proteomics 5, 161–168.
Nagashima, T., Shimodaira, H., Ide, K., Nakakuki, T., Tani, Y., Takahashi, K.,
et al. (2007). Quantitative transcriptional control of ErbB receptor signaling
undergoes graded to biphasic response for cell differentiation. J. Biol. Chem.
282, 4045–4056. doi: 10.1074/jbc.M608653200
Neal, D. E., Marsh, C., Bennett, M. K., Abel, P. D., Hall, R. R., Sainsbury, J. R.,
et al. (1985). Epidermal-growth-factor receptors in human bladder cancer:
comparison of invasive and superficial tumours. Lancet 1, 366–368. doi:
10.1016/S0140-6736(85)91386-8
Nedergaard, M. K., Hedegaard, C. J., and Poulsen, H. S. (2012). Targeting the
epidermal growth factor receptor in solid tumor malignancies. Biodrugs 26,
83–99. doi: 10.2165/11599760-000000000-00000
Neerincx, A., Castro, W., Guarda, G., and Kufer, T. A. (2013). NLRC5, at the heart
of antigen presentation. Front. Immunol. 4:397. doi: 10.3389/fimmu.2013.00397
Niikura, H., Sasano, H., Sato, S., and Yajima, A. (1997). Expression of epidermal
growth factor-related proteins and epidermal growth factor receptor in
common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 16, 60–68. doi:
10.1097/00004347-199701000-00010
Nistico, P., Mottolese, M., Cascioli, S., Benevolo, M., Del Bello, D., Di Modugno, F.,
et al. (1999). Host immunosurveillance contributes to the control of erbB-2
overexpression in HLA-A2-breast-cancer patients. Int. J. Cancer 84, 598–603.
doi: 10.1002/(SICI)1097-0215(19991222)84:6<598::AID-IJC10>3.0.CO;2-7
Nistico, P., Mottolese, M., Mammi, C., Benevolo, M., Del Bello, D., Rubiu, O., et al.
(1997). Low frequency of ErbB-2 proto-oncogene overexpression in human
leukocyte antigen-A2-positive breast cancer patients. J. Natl. Cancer Inst. 89,
319–321. doi: 10.1093/jnci/89.4.319
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., and Salomon, D. S. (2003a).
Target-based agents against ErbB receptors and their ligands: a novel approach
to cancer treatment. Endocr. Relat. Cancer 10, 1–21. doi: 10.1677/erc.0.0100001
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R.,
et al. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene
366, 2–16. doi: 10.1016/j.gene.2005.10.018
Normanno, N., Maiello, M. R., and De Luca, A. (2003b). Epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex
mechanism of action? J. Cell. Physiol. 194, 13–19. doi: 10.1002/jcp.10194
Nouri, A. M., Hussain, R. F., and Oliver, R. T. (1995). Epidermal growth factor-
induced protection of tumour cell susceptibility to cytolysis. Eur. J. Cancer 31a,
963–969. doi: 10.1016/0959-8049(95)00120-4
O-Charoenrat, P., Rhys-Evans, P. H., Modjtahedi, H., and Eccles, S. A. (2002). The
role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.
Oral Oncol. 38, 627–640. doi: 10.1016/S1368-8375(02)00029-5
Okita, R., Wolf, D., Yasuda, K., Maeda, A., Yukawa, T., Saisho, S., et al. (2015).
Contrasting effects of the cytotoxic anticancer drug gemcitabine and the
EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated cytotoxicity via
regulation of NKG2D ligand in non-small-cell lung cancer cells. PLoS ONE
10:e0139809. doi: 10.1371/journal.pone.0139809
Okwan-Duodu, D., Pollack, B. P., Lawson, D., and Khan, M. K. (2015). Role of
radiation therapy as immune activator in the era of modern immunotherapy
for metastatic malignant melanoma. Am. J. Clin. Oncol. 38, 119–125. doi:
10.1097/COC.0b013e3182940dc3
Oliveras-Ferraros, C., Cufi, S., Vazquez-Martin, A., Menendez, O. J., Bosch-
Barrera, J., Martin-Castillo, B., et al. (2012). Metformin rescues cell surface
major histocompatibility complex class I (MHC-I) deficiency caused by
oncogenic transformation. Cell Cycle 11, 865–870. doi: 10.4161/cc.11.5.19252
Oxnard, G. R., Binder, A., and Janne, P. A. (2013). New targetable oncogenes
in non-small-cell lung cancer. J. Clin. Oncol. 31, 1097–1104. doi:
10.1200/JCO.2012.42.9829
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004).
EGFR mutations in lung cancer: correlation with clinical response to gefitinib
therapy. Science 304, 1497–1500. doi: 10.1126/science.1099314
Paff, M., Alexandru-Abrams, D., Hsu, F. P., and Bota, D. A. (2014). The
evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma
multiforme patients. Hum. Vaccin. Immunother. 10, 3322–3331. doi:
10.4161/21645515.2014.983002
Park, S. K., Miller, R., Krane, I., and Vartanian, T. (2001). The erbB2 gene
is required for the development of terminally differentiated spinal cord
oligodendrocytes. J. Cell Biol. 154, 1245–1258. doi: 10.1083/jcb.200104025
Pedersen, M. W., Pedersen, N., Damstrup, L., Villingshoj, M., Sonder, S. U.,
Rieneck, K., et al. (2005). Analysis of the epidermal growth factor
receptor specific transcriptome: effect of receptor expression level and
an activating mutation. J. Cell. Biochem. 96, 412–427. doi: 10.1002/jcb.
20554
Pennini, M. E., Pai, R. K., Schultz, D. C., Boom, W. H., and Harding, C. V. (2006).
Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-gamma-induced
chromatin remodeling of MHC2TA by TLR2 and MAPK signaling. J. Immunol.
176, 4323–4330. doi: 10.4049/jimmunol.176.7.4323
Pines, G., Kostler, W. J., and Yarden, Y. (2010). Oncogenic mutant forms of EGFR:
lessons in signal transduction and targets for cancer therapy. FEBS Lett. 584,
2699–2706. doi: 10.1016/j.febslet.2010.04.019
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I.,
Klapper, L., et al. (1996). Diversification of Neu differentiation factor and
epidermal growth factor signaling by combinatorial receptor interactions.
EMBO J. 15, 2452–2467.
Frontiers in Pharmacology | www.frontiersin.org 15 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 16
Kersh et al. ErbB/HER Signaling and MHC Expression
Pollack, B. P., Sapkota, B., and Cartee, T. V. (2011). Epidermal growth factor
receptor inhibition augments the expression of MHC class I and II genes. Clin.
Cancer Res. 17, 4400–4413. doi: 10.1158/1078-0432.CCR-10-3283
Prenzel, N., Zwick, E., Leserer, M., and Ullrich, A. (2000). Tyrosine kinase
signalling in breast cancer. Epidermal growth factor receptor: convergence
point for signal integration and diversification. Breast Cancer Res. 2, 184–190.
Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R.,
et al. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent
mutations in ERBB4. Nat. Genet. 41, 1127–1132. doi: 10.1038/ng.438
Qi, Y., Operario, D. J., Georas, S. N., and Mosmann, T. R. (2012). The acute
environment, rather than T cell subset pre-commitment, regulates expression
of the human T cell cytokine amphiregulin. PLoS ONE 7:e39072. doi:
10.1371/journal.pone.0039072
Raj, E. H., Skinner, A., Mahji, U., Nirmala, K. N., Ravichandran, K., Shanta, V., et al.
(2001). Neuregulin 1-alpha expression in locally advanced breast cancer. Breast
10, 41–45. doi: 10.1054/brst.2000.0182
Reith, W., and Boss, J. M. (2008). New dimensions of CIITA. Nat. Immunol. 9,
713–714. doi: 10.1038/ni0708-713
Roche, P. A., and Furuta, K. (2015). The ins and outs of MHC class II-mediated
antigen processing and presentation. Nat. Rev. Immunol. 15, 203–216. doi:
10.1038/nri3818
Rodon, J., Dienstmann, R., Serra, V., and Tabernero, J. (2013). Development of
PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol.
10, 143–153. doi: 10.1038/nrclinonc.2013.10
Rolitsky, C. D., Theil, K. S., Mcgaughy, V. R., Copeland, L. J., and Niemann,
T. H. (1999). HER-2/neu amplification and overexpression in endometrial
carcinoma. Int. J. Gynecol. Pathol. 18, 138–143. doi: 10.1097/00004347-
199904000-00007
Roskoski, R. Jr. (2014). The ErbB/HER family of protein-tyrosine kinases and
cancer. Pharmacol. Res. 79, 34–74. doi: 10.1016/j.phrs.2013.11.002
Rusch, V., Klimstra, D., Venkatraman, E., Pisters, P. W., Langenfeld, J., and
Dmitrovsky, E. (1997). Overexpression of the epidermal growth factor receptor
and its ligand transforming growth factor alpha is frequent in resectable non-
small cell lung cancer but does not predict tumor progression. Clin. Cancer Res.
3, 515–522.
Rutledge, W. C., Kong, J., Gao, J., Gutman, D. A., Cooper, L. A., Appin, C., et al.
(2013). Tumor-infiltrating lymphocytes in glioblastoma are associated with
specific genomic alterations and related to transcriptional class. Clin. Cancer
Res. 19, 4951–4960. doi: 10.1158/1078-0432.CCR-13-0551
Saba, N. F., Wilson, M., Doho, G., Dasilva, J., Benjamin Isett, R., Newman, S.,
et al. (2015). Mutation and transcriptional profiling of formalin-fixed paraffin
embedded specimens as companion methods to immunohistochemistry for
determining therapeutic targets in Oropharyngeal Squamous Cell Carcinoma
(OPSCC): a pilot of proof of principle. Head Neck Pathol. 9, 223–235. doi:
10.1007/s12105-014-0566-0
Sabbatino, F., Wang, Y., Scognamiglio, G., Favoino, E., Feldman, S. A.,
Villani, V., et al. (2016). Antitumor activity of BRAF inhibitor and IFNalpha
combination in BRAF-mutant melanoma. J. Natl. Cancer Inst. 108, djv435. doi:
10.1093/jnci/djv435
Saffari, B., Jones, L. A., El-Naggar, A., Felix, J. C., George, J., and Press, M. F. (1995).
Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial
cancers: correlation with overall survival. Cancer Res. 55, 5693–5698.
Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal
growth factor-related peptides and their receptors in human malignancies. Crit.
Rev. Oncol. Hematol. 19, 183–232. doi: 10.1016/1040-8428(94)00144-I
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., and Bigner,
D. D. (2008). Tumor-specific immunotherapy targeting the EGFRvIII mutation
in patients with malignant glioma. Semin. Immunol. 20, 267–275. doi:
10.1016/j.smim.2008.04.001
Sandgren, E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L., and Lee, D. C.
(1990). Overexpression of TGF alpha in transgenic mice: induction of epithelial
hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121–
1135. doi: 10.1016/0092-8674(90)90075-P
Sapkota, B., Hill, C. E., and Pollack, B. P. (2013). Vemurafenib enhances MHC
induction in BRAFV600E homozygous melanoma cells. Oncoimmunology 2,
e22890. doi: 10.4161/onci.22890
Sato, K., Moriyama, M., Mori, S., Saito, M., Watanuki, T., Terada, K., et al.
(1992). An immunohistologic evaluation of C-erbB-2 gene product in patients
with urinary bladder carcinoma. Cancer 70, 2493–2498. doi: 10.1002/1097-
0142(19921115)70:10<2493::AID-CNCR2820701017>3.0.CO;2-K
Sauter, G., Moch, H., Moore, D., Carroll, P., Kerschmann, R., Chew, K., et al.
(1993). Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer
Res. 53, 2199–2203.
Schaefer, G., Shao, L., Totpal, K., and Akita, R. W. (2007). Erlotinib directly inhibits
HER2 kinase activation and downstream signaling events in intact cells lacking
epidermal growth factor receptor expression. Cancer Res. 67, 1228–1238. doi:
10.1158/0008-5472.CAN-06-3493
Scher, H. I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., et al. (1995).
Changing pattern of expression of the epidermal growth factor receptor and
transforming growth factor alpha in the progression of prostatic neoplasms.
Clin. Cancer Res. 1, 545–550.
Schneble, E. J., Berry, J. S., Trappey, F. A., Clifton, G. T., Ponniah, S., Mittendorf, E.,
et al. (2014). The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) in breast
cancer patients at risk for recurrence: correlation of immunologic data with
clinical response. Immunotherapy 6, 519–531. doi: 10.2217/imt.14.22
Schneider, M. R., Antsiferova, M., Feldmeyer, L., Dahlhoff, M., Bugnon, P.,
Hasse, S., et al. (2008). Betacellulin regulates hair follicle development and hair
cycle induction and enhances angiogenesis in wounded skin. J. Invest. Dermatol.
128, 1256–1265. doi: 10.1038/sj.jid.5701135
Schneider, M. R., and Wolf, E. (2009). The epidermal growth factor receptor ligands
at a glance. J. Cell. Physiol. 218, 460–466. doi: 10.1002/jcp.21635
Schreiber, A. B., Schlessinger, J., and Edidin, M. (1984). Interaction between major
histocompatibility complex antigens and epidermal growth factor receptors on
human cells. J. Cell Biol. 98, 725–731. doi: 10.1083/jcb.98.2.725
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., et al. (2014).
A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512,
324–327. doi: 10.1038/nature13387
Seliger, B. (2008a). Different regulation of MHC class I antigen processing
components in human tumors. J. Immunotoxicol. 5, 361–367. doi:
10.1080/15476910802482870
Seliger, B. (2008b). Molecular mechanisms of MHC class I abnormalities and APM
components in human tumors. Cancer Immunol. Immunother. 57, 1719–1726.
doi: 10.1007/s00262-008-0515-4
Seliger, B. (2014). The link between MHC class I abnormalities of
tumors, oncogenes, tumor suppressor genes, and transcription factors.
J. Immunotoxicol. 11, 308–310. doi: 10.3109/1547691X.2013.875084
Seliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampe, R., et al.
(1998). Down-regulation of the MHC class I antigen-processing machinery
after oncogenic transformation of murine fibroblasts. Eur. J. Immunol.
28, 122–133. doi: 10.1002/(SICI)1521-4141(199801)28:01<122::AID-
IMMU122>3.0.CO;2-F
Seliger, B., Harders, C., Wollscheid, U., Staege, M. S., Reske-Kunz, A. B.,
and Huber, C. (1996). Suppression of MHC class I antigens in oncogenic
transformants: association with decreased recognition by cytotoxic T
lymphocytes. Exp. Hematol. 24, 1275–1279.
Seliger, B., and Kiessling, R. (2013). The two sides of HER2/neu: immune
escape versus surveillance. Trends Mol. Med. 19, 677–684. doi:
10.1016/j.molmed.2013.08.003
Seliger, B., Killian, M., and Pfizenmaier, K. (1988). Distinct mechanisms of
interferon-gamma and tumor necrosis factor-alpha action in oncogene-
transformed mouse fibroblasts. J. Cell. Biochem. 38, 205–212. doi:
10.1002/jcb.240380308
Seliger, B., Maeurer, M. J., and Ferrone, S. (2000). Antigen-processing
machinery breakdown and tumor growth. Immunol. Today 21, 455–464. doi:
10.1016/S0167-5699(00)01692-3
Seliger, B., and Pfizenmaier, K. (1989). Post-transcriptional downregulation of
MHC class I expression in oncogene-transformed cells is reverted by IFN-
gamma and TNF-alpha. J. Immunogenet. 16, 315–320. doi: 10.1111/j.1744-
313X.1989.tb00477.x
Sers, C., Kuner, R., Falk, C. S., Lund, P., Sueltmann, H., Braun, M., et al. (2009).
Down-regulation of HLA Class I and NKG2D ligands through a concerted
action of MAPK and DNA methyltransferases in colorectal cancer cells. Int. J.
Cancer 125, 1626–1639. doi: 10.1002/ijc.24557
Shintani, S., Funayama, T., Yoshihama, Y., Alcalde, R. E., and Matsumura, T.
(1995). Prognostic significance of ERBB3 overexpression in oral squamous cell
carcinoma. Cancer Lett. 95, 79–83. doi: 10.1016/0304-3835(95)03866-U
Frontiers in Pharmacology | www.frontiersin.org 16 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 17
Kersh et al. ErbB/HER Signaling and MHC Expression
Shostak, K., and Chariot, A. (2015). EGFR and NF-kappaB: partners in cancer.
Trends Mol. Med. 21, 385–393. doi: 10.1016/j.molmed.2015.04.001
Sibilia, M., Steinbach, J. P., Stingl, L., Aguzzi, A., and Wagner, E. F. (1998). A strain-
independent postnatal neurodegeneration in mice lacking the EGF receptor.
EMBO J. 17, 719–731. doi: 10.1093/emboj/17.3.719
Sibilia, M., and Wagner, E. F. (1995). Strain-dependent epithelial defects in mice
lacking the EGF receptor. Science 269, 234–238. doi: 10.1126/science.7618085
Sidaway, P. (2015). Targeted therapies: drug addiction revealed in BRAF and
MEK inhibitor-resistant melanoma cells. Nat. Rev. Clin. Oncol. 12:189. doi:
10.1038/nrclinonc.2015.28
Slattery, M. L., John, E. M., Stern, M. C., Herrick, J., Lundgreen, A., Giuliano,
A. R., et al. (2013). Associations with growth factor genes (FGF1, FGF2, PDGFB,
FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the breast
cancer health disparities study. Breast Cancer Res. Treat. 140, 587–601. doi:
10.1007/s10549-013-2644-5
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A.,
et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N. Engl. J. Med. 371, 2189–2199. doi: 10.1056/NEJMoa1406498
Sorensen, M. R., Holst, P. J., Pircher, H., Christensen, J. P., and Thomsen, A. R.
(2009). Vaccination with an adenoviral vector encoding the tumor antigen
directly linked to invariant chain induces potent CD4(+) T-cell-independent
CD8(+) T-cell-mediated tumor control. Eur. J. Immunol. 39, 2725–2736. doi:
10.1002/eji.200939543
Soung, Y. H., Lee, J. W., Kim, S. Y., Wang, Y. P., Jo, K. H., Moon, S. W., et al.
(2006). Somatic mutations of the ERBB4 kinase domain in human cancers. Int.
J. Cancer 118, 1426–1429. doi: 10.1002/ijc.21507
Sporn, M. B., and Roberts, A. B. (1985). Autocrine growth factors and cancer.
Nature 313, 745–747. doi: 10.1038/313745a0
Tanner, M., Hollmen, M., Junttila, T. T., Kapanen, A. I., Tommola, S.,
Soini, Y., et al. (2005). Amplification of HER-2 in gastric carcinoma:
association with Topoisomerase IIalpha gene amplification, intestinal type,
poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273–278. doi:
10.1093/annonc/mdi064
Thorpe, L. M., Yuzugullu, H., and Zhao, J. J. (2015). PI3K in cancer: divergent roles
of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15,
7–24. doi: 10.1038/nrc3860
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U.,
Yee, D., et al. (1995). Targeted disruption of mouse EGF receptor: effect
of genetic background on mutant phenotype. Science 269, 230–234. doi:
10.1126/science.7618084
Troyer, K. L., and Lee, D. C. (2001). Regulation of mouse mammary gland
development and tumorigenesis by the ERBB signaling network. J. Mammary
Gland Biol. Neoplasia 6, 7–21. doi: 10.1023/A:1009560330359
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., et al.
(1996). A hierarchical network of interreceptor interactions determines signal
transduction by Neu differentiation factor/neuregulin and epidermal growth
factor. Mol. Cell. Biol. 16, 5276–5287. doi: 10.1128/MCB.16.10.5276
Umelo, I., Noeparast, A., Chen, G., Renard, M., Geers, C., Vansteenkiste, J.,
et al. (2016). Identification of a novel HER3 activating mutation
homologous to EGFR-L858R in lung cancer. Oncotarget 7, 3068–3083.
doi: 10.18632/oncotarget.6585
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L.,
et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic
melanoma. Science 350, 207–211. doi: 10.1126/science.aad0095
van den Elsen, P. J. (2011). Expression regulation of major histocompatibility
complex class I and class II encoding genes. Front. Immunol. 2:48. doi:
10.3389/fimmu.2011.00048
van den Elsen, P. J., Gobin, S. J., Van Eggermond, M. C., and Peijnenburg, A. (1998).
Regulation of MHC class I and II gene transcription: differences and similarities.
Immunogenetics 48, 208–221. doi: 10.1007/s002510050425
van den Elsen, P. J., Holling, T. M., Kuipers, H. F., and Van Der Stoep, N. (2004).
Transcriptional regulation of antigen presentation. Curr. Opin. Immunol. 16,
67–75. doi: 10.1016/j.coi.2003.11.015
van der Burg, S. H., Arens, R., Ossendorp, F., Van Hall, T., and Melief, C. J. (2016).
Vaccines for established cancer: overcoming the challenges posed by immune
evasion. Nat. Rev. Cancer 16, 219–233. doi: 10.1038/nrc.2016.16
van Rooij, N., Van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B.,
et al. (2013). Tumor exome analysis reveals neoantigen-specific T-cell reactivity
in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442. doi:
10.1200/JCO.2012.47.7521
Vanguri, V., Govern, C. C., Smith, R., and Huseby, E. S. (2013). Viral antigen
density and confinement time regulate the reactivity pattern of CD4 T-cell
responses to vaccinia virus infection. Proc. Natl. Acad. Sci. U.S.A. 110, 288–293.
doi: 10.1073/pnas.1208328110
Vantourout, P., Willcox, C., Turner, A., Swanson, C. M., Haque, Y., Sobolev, O.,
et al. (2014). Immunological visibility: posttranscriptional regulation of human
NKG2D ligands by the EGF receptor pathway. Sci. Transl. Med. 6, 231ra249.
doi: 10.1126/scitranslmed.3007579
Vassar, R., and Fuchs, E. (1991). Transgenic mice provide new insights into the role
of TGF-alpha during epidermal development and differentiation. Genes Dev. 5,
714–727. doi: 10.1101/gad.5.5.714
Voong, L. N., Slater, A. R., Kratovac, S., and Cressman, D. E. (2008). Mitogen-
activated protein kinase ERK1/2 regulates the class II transactivator. J. Biol.
Chem. 283, 9031–9039. doi: 10.1074/jbc.M706487200
Ward, J. P., Gubin, M. M., and Schreiber, R. D. (2016). The role of neoantigens in
naturally occurring and therapeutically induced immune responses to cancer.
Adv. Immunol. 130, 25–74. doi: 10.1016/bs.ai.2016.01.001
Wargo, J. A., Cooper, Z. A., and Flaherty, K. T. (2014). Universes collide: combining
immunotherapy with targeted therapy for cancer. Cancer Discov. 4, 1377–1386.
doi: 10.1158/2159-8290.CD-14-0477
Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., and
Ohgaki, H. (1996). Overexpression of the EGF receptor and p53 mutations are
mutually exclusive in the evolution of primary and secondary glioblastomas.
Brain Pathol. 6, 217–223; discussion223–214. doi: 10.1111/j.1750-3639.1996.
tb00848.x
Weiner, D. B., Nordberg, J., Robinson, R., Nowell, P. C., Gazdar, A., Greene, M. I.,
et al. (1990). Expression of the neu gene-encoded protein (P185neu) in human
non-small cell carcinomas of the lung. Cancer Res. 50, 421–425.
Whipple, C. A., Boni, A., Fisher, J. L., Hampton, T. H., Tsongalis, G. J.,
Mellinger, D. L., et al. (2016). The mitogen-activated protein kinase
pathway plays a critical role in regulating immunological properties of
BRAF mutant cutaneous melanoma cells. Melanoma Res. 26, 223–235. doi:
10.1097/CMR.0000000000000244
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., and Melero, I.
(2016). Emerging opportunities and challenges in cancer immunotherapy. Clin.
Cancer Res. 22, 1845–1855. doi: 10.1158/1078-0432.CCR-16-0049
Wiesen, J. F., Young, P., Werb, Z., and Cunha, G. R. (1999). Signaling through
the stromal epidermal growth factor receptor is necessary for mammary ductal
development. Development 126, 335–344.
Wong, R. W. (2003). Transgenic and knock-out mice for deciphering the roles of
EGFR ligands. Cell. Mol. Life Sci. 60, 113–118. doi: 10.1007/s000180300007
Wong, R. W., Kwan, R. W., Mak, P. H., Mak, K. K., Sham, M. H., and
Chan, S. Y. (2000). Overexpression of epidermal growth factor induced
hypospermatogenesis in transgenic mice. J. Biol. Chem. 275, 18297–18301. doi:
10.1074/jbc.M001965200
Wu, S. J., Jiang, S. Y., Wu, J., and Xiong, G. L. (2015). Association between EGF
+61 A>G polymorphism and gastric cancer risk: a meta-analysis. J. Huazhong
Univ. Sci. Technolog. Med. Sci. 35, 327–332. doi: 10.1007/s11596-015-
1432-3
Wu, X., Kong, X., Luchsinger, L., Smith, B. D., and Xu, Y. (2009). Regulating
the activity of class II transactivator by posttranslational modifications:
exploring the possibilities. Mol. Cell. Biol. 29, 5639–5644. doi: 10.1128/MCB.
00661-09
Xian, C. J., and Zhou, X. F. (2004). EGF family of growth factors: essential roles and
functional redundancy in the nerve system. Front. Biosci. 9:85–92.
Xie, W., Paterson, A. J., Chin, E., Nabell, L. M., and Kudlow, J. E. (1997).
Targeted expression of a dominant negative epidermal growth factor receptor
in the mammary gland of transgenic mice inhibits pubertal mammary duct
development. Mol. Endocrinol. 11, 1766–1781. doi: 10.1210/mend.11.12.0019
Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Beger, H. G., and Korc, M.
(1993a). Coexpression of epidermal growth factor receptor and ligands in
human pancreatic cancer is associated with enhanced tumor aggressiveness.
Anticancer. Res. 13, 565–569.
Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Kunz, J., Beger, H. G.,
et al. (1993b). Overexpression of HER2/neu oncogene in human pancreatic
carcinoma. Hum. Pathol. 24, 1127–1134. doi: 10.1016/0046-8177(93)90194-L
Frontiers in Pharmacology | www.frontiersin.org 17 September 2016 | Volume 7 | Article 327
fphar-07-00327 September 22, 2016 Time: 16:0 # 18
Kersh et al. ErbB/HER Signaling and MHC Expression
Yanagawa, Y., Iijima, N., Iwabuchi, K., and Onoe, K. (2002). Activation of
extracellular signal-related kinase by TNF-alpha controls the maturation and
function of murine dendritic cells. J. Leukoc. Biol. 71, 125–132.
Yano, T., Doi, T., Ohtsu, A., Boku, N., Hashizume, K., Nakanishi, M., et al.
(2006). Comparison of HER2 gene amplification assessed by fluorescence in situ
hybridization and HER2 protein expression assessed by immunohistochemistry
in gastric cancer. Oncol. Rep. 15, 65–71.
Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B.,
et al. (2016). NLRC5/MHC class I transactivator is a target for immune
evasion in cancer. Proc. Natl. Acad. Sci. U.S.A. 113, 5999–6004. doi:
10.1073/pnas.1602069113
Zaiss, D. M., Gause, W. C., Osborne, L. C., and Artis, D. (2015). Emerging functions
of amphiregulin in orchestrating immunity, inflammation, and tissue repair.
Immunity 42, 216–226. doi: 10.1016/j.immuni.2015.01.020
Zaiss, D. M., Van Loosdregt, J., Gorlani, A., Bekker, C. P., Grone, A., Sibilia, M.,
et al. (2013). Amphiregulin enhances regulatory T cell-suppressive function
via the epidermal growth factor receptor. Immunity 38, 275–284. doi:
10.1016/j.immuni.2012.09.023
Zaiss, D. M., Yang, L., Shah, P. R., Kobie, J. J., Urban, J. F., and Mosmann, T. R.
(2006). Amphiregulin, a TH2 cytokine enhancing resistance to nematodes.
Science 314:1746. doi: 10.1126/science.1133715
Zaks, T. Z., and Rosenberg, S. A. (1998). Immunization with a peptide epitope
(p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes
that fail to recognize HER-2/neu+ tumors. Cancer Res. 58, 4902–4908.
Zhao, Y., and Adjei, A. A. (2014). The clinical development of MEK
inhibitors. Nat. Rev. Clin. Oncol. 11, 385–400. doi: 10.1038/nrclinonc.
2014.83
Zhou, Y., and Brattain, M. G. (2005). Synergy of epidermal growth factor receptor
kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon
carcinoma cells is associated with induction of apoptosis. Cancer Res. 65,
5848–5856. doi: 10.1158/0008-5472.CAN-04-3509
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Kersh, Sasaki, Cooper, Kissick and Pollack. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 18 September 2016 | Volume 7 | Article 327
